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PREFACE 
 
The American Cancer Society was founded in 1913, and since that time, has 
promoted cancer awareness. Educational efforts began with medical professionals and 
later expanded to include the general public. Over the last century, their efforts, and 
others like theirs, have greatly improved public awareness of the disease, funding, and 
advocacy for cancer related programs.  There have been many advances in basic 
knowledge of most cancers.  Pioneering research in prostate cancer in 1941 by Huggins 
and Hodges demonstrated that castration caused cancer regression. Castration caused 
disease regression by removing androgens and therefore preventing the activation of the 
androgen receptor. This breakthrough provided a way to control tumor growth, but 
unfortunately they discovered that prostate cancer recurred independently of androgens.  
Although their work provided perhaps the biggest breakthrough in the prostate cancer 
field, earning them the Nobel Prize, the mechanisms by which prostate cancer and 
androgen-independent disease develops remains elusive some 66 years later. The 
androgen receptor remains a persistently pursued target in prostate cancer research today 
and anti-androgen therapy remains the most effective treatment. Laboratories throughout 
the world strive to understand how it is controlled in all stages of prostate development 
and cancer progression.  Our laboratory has developed the hypothesis that there is a sub-
set of anti-androgen-regulated genes that may allow the androgen receptor to escape anti-
androgen therapy and promote disease progression. This is a compelling idea – perhaps 
the treatment itself drives disease progression.  This research project specifically 
addresses this hypothesis by focusing on the oncogene DJ-1 in prostate cancer.  We 
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determined that DJ-1 is a novel androgen receptor binding partner regulated by androgens 
and anti-androgens and that DJ-1 expression increases in primary prostate cancer 
following androgen deprivation (anti-androgen) therapy. Thus, increased DJ-1 expression 
may promote androgen receptor activity and serve as a marker for the development of 
hormone-refractory prostate cancer. 
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CHAPTER I 
 
 INTRODUCTION 
 
Prostate Biology and Structure 
 The prostate is a male accessory reproductive gland found in all mammals that 
aids in liquefying the seminal fluid. Physiologic parallels are numerous between species, 
but there are few anatomic similarities. For example, in humans and dogs, the prostate is 
located at the bladder neck, while in mice and rats, the prostate is a combination of paired 
glandular organs (1).  Mouse and rat prostate is discussed in Chapter V. 
 
 
 
 
 
 
 
 
 
 
Figure 1. The adult prostate and surrounding structures.  The base of the 
prostate is located at the bladder neck.  The urethra bisects the prostate. Image 
taken from (1). 
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Figure 2: Prostatic Zones.  Lateral A) and Coronal B) views of the prostatic 
zones. The four histologically distinct zones are shown: anterior fibromuscular 
stroma, the central zone, the transitional zone, and the peripheral zone. Figure 
taken from (1). 
 
 
The human prostate changes little in size from birth until puberty.  At puberty, the 
prostate undergoes rapid growth and reaches an average adult weight of approximately 40 
grams.  Structurally, the human prostate resembles a truncated cone that is bisected by the 
urethra (Figure 1). Distinct anatomic lobes were not defined for the human prostate until 
1975.  Tissel and Salander described four anatomically distinct lobes that were arranged 
in an “onion” pattern.  The anatomical pattern they defined was confirmed by other 
investigators and is used today. The prostate is composed of the central, transition, 
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peripheral zones, and a region of anterior fibromuscular stoma (Figure 2).  As the name 
indicates, the anterior fibromuscular stroma is the most anterior prostatic structure. 
Posteriorly to the stromal region are the paired central zones. Interior to the central zones 
are the transition zones which are located on either side of the urethra. The transition 
zones represent the smallest zone in the normal prostate. Lastly, the peripheral zone is 
located on the posterior side of the prostate.  The peripheral zone is the largest region of 
the normal adult prostate (Figure 2) 
 
Histologically, prostatic glands are composed of several cell types (Figure 3).  The 
predominant cells are tall columnar luminal epithelial cells which are androgen-dependent 
and produce prostatic secretions (2, 3).  Luminal epithelial cells are characterized by 
expression of androgen receptor and cytokeratins 8 and 18. Basal cells are the second 
most abundant cell type.  Basal cells form a continuous layer between the luminal cells 
and the basement membrane/basal lamina (2).  Cytokeratins 4 and 14 as well as p63 are 
basal cell markers. The third prostatic epithelial cell type is neuroendocrine cells which 
are androgen-independent and are dispersed throughout the basal layer (4).  
Neuroendocrine cells are a minor population of cells in the normal prostate and express 
chromogranin A, serotonin, and neuropeptides.  A thick layer of stroma surrounds the 
epithelial glands and is composed primarily of smooth muscle but also contains 
fibroblastic, neuronal, vascular, and lymphatic cell types (5). Stromal markers include 
smooth muscle alpha-actin and vimentin. 
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Figure 3: Schematic Diagram of the Cell Types in an Adult Human Prostatic 
Duct. Relative abundance of epithelial cell types is depicted.  Figure from (2). 
 
 
In most mammals, the prostate is not of great pathological significance. For 
humans, this is not the case.  The human prostate is associated with a number of diseases 
which are discussed.   
 
Prostatic Diseases 
 Unlike most mammals, the human prostate is associated with both benign and 
malignant conditions. The presence of LUTS, or Lower Urinary Tract Symptoms, such as 
frequent urination, urgent need to urinate, and nocturia are common to all prostatic 
diseases and are typically the reason men see their doctor. These symptoms alone could 
be evidence of either a benign or a malignant condition.  Prostatitis and Benign Prostatic 
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Hyperplasia are two common non-malignant conditions that affect the prostate while 
adenocarcinoma is the most common malignant prostatic disease.  
 
Prostatitis 
Prostatitis is an inflammation of the prostate that encompasses four disorders: 
acute bacterial prostatitis, chronic bacterial prostatitis, chronic pelvic pain syndrome, and 
asymptomatic inflammatory prostatitis. Acute prostatitis is the least common of the four 
types.  It is caused by a bacterial infection that often results in fever, lower back pain, and 
a burning sensation during urination in addition to general LUTS symptoms.  Acute 
prostatitis is easily cured with antibiotics.  Chronic bacterial prostatitis is also relatively 
uncommon and is essentially acute prostatitis accompanied by an underlying problem in 
the prostate allowing chronic infection.  This type of prostatitis is treated with antibiotics, 
but may not be curable. The third, and most common, type of prostatitis is known as 
chronic pelvic pain syndrome.  It can be either inflammatory or non-inflammatory and 
symptoms often appear and disappear unexpectedly.  This type of prostatitis is the least 
well understood and the treatments vary between patients.  Asymptomatic inflammatory 
prostatitis is the fourth variety and occurs when the patient has no symptoms, but 
inflammatory cells are present in the semen.  
 
Prostatitis in itself is a relatively minor disorder of the prostate, but inflammatory 
markers have recently been correlated with cancer risk (6, 7).  However, other studies 
determined that clinical prostatitis did not increase occurrence of prostate cancer (8). 
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These controversial results indicate that the effects of prostattis on prstate cancer risk or 
initiation require further investigation. 
 
Benign Prostatic Hyperplasia (BPH) 
BPH is another common disease of the prostate.  BPH occurs in the transitional 
zone resulting in an age-dependent enlargement of the gland. Early development of BPH 
usually occurs after age 40 with prevalence rising to over 50% by age 60, and may reach 
90% in men over 85 years  (9, 10).  Approximately 50% of men diagnosed have moderate 
to severe LUTS (9). Both stromal and epithelial hyperplasia have been documented in 
BPH, but it is typically accepted that the stromal:epithelial cell ratio is higher in BPH than 
normal prostate (9).  
 
BPH is diagnosed by testing the rate of urine flow, digital rectal examination, as 
well as prostate-specific antigen (PSA) levels.  Decreased urine flow rate may indicate 
that a patient has an enlarged prostate, which can be confirmed with a digital rectal 
examination. Blood tests are performed to determine the levels of PSA, a serine protease 
that functions to liquefy semen.  If the prostate is enlarged but PSA levels are normal 
(lower than 4 ng/mL), then BPH rather than prostate cancer is likely the cause of the 
patient’s LUTS.  
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Prostate Cancer 
The most common prostate malignancy is adenocarcinoma. Unlike BPH, prostate 
adenocarcinoma occurs primarily in the peripheral zone. Prostate Cancer (PCa) is the 
most prevalent cancer in males, affecting 1 in 9 men between 60 and 70 years old. There 
are multiple risk factors for the development of PCa, but age is the most significant.  
Other risk factors include race, family history, and environmental aspects such as diet 
(11). Studies of age-specific incidence have revealed that risk increases significantly after 
age 55 and peaks at age 70-74. Autopsy studies have revealed the long latency of PCa 
because lesions have been found in the prostates of men in their 20s and 30s (11). Race 
has been added to the risk factor list due to the 60% higher incidence in African-
Americans as compared to whites (11). Mortality rates are also higher in African-
Americans, although the causes are unclear (11).  Since the 1950s epidemiological studies 
determined that having a first-degree relative with PCa increased an individual’s risk of 
developing the disease by 2-3 fold, (reviewed in (11)). Further, epidemiology has 
determined that the prevalence of PCa is much higher in the United States than in other 
parts of the world.  In Asia for example, PCa rates are very low, but Asian men who 
immigrate to the United States have similar rates of PCa to American men, indicating that 
this difference is related to dietary and environmental differences rather than genetic ones 
(2). There is a genetic component to PCa risk, however.  Two familial susceptibility loci 
have been mapped to the X chromosome and to a region of chromosome 1q (2, 12, 13). 
The impact of these factors on the development and progression of PCa is currently an 
area of intense investigation. 
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Although controversy exists as to whether prostatitis or BPH increase PCa risk or 
the development of pre-neoplastic lesions, prostatic-intraepithelial neoplasia (PIN) has 
been accepted as a precursor to cancer (14).  PIN lesions can be described as either low-
grade (LGPIN) or high-grade (HGPIN) depending on the level of architectural 
abnormalities.  LGPIN resembles normal prostate, but tufting of the luminal epithelial 
cells exists. HGPIN is considered an immediate precursor to early invasive carcinoma. 
Figure 4 depicts the progression from normal prostate epithelium to metastatic cancer and 
well-defined architectural changes that occur during this progression. For example, there 
is typically a loss of basal cells in PIN, but the basal lamina/basement membrane is intact.  
Once epithelial cells invade the basal lamina, the lesion would be classified as invasive 
carcinoma.  Metastasis is defined by migration and growth of prostatic epithelial cells to 
distant sites in the body (Figure 4).   
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Figure 4: Pathway for Human PCa Progression. Stages of progression are 
correlated with specific changes such as loss of basal cells or invasion of the basal 
lamina. Candidate genes for the progression of PCa are shown. Figure taken from 
(2). 
 
 Although there are relatively clear guidelines for classification of PIN versus 
carcinoma, the heterogeneous and multi-focal nature of PCa provides a challenge to 
researchers. When PCa samples are examined histologically, there will typically be a 
combination of normal, pre-neoplastic, and neoplastic foci of varying severity throughout 
the tissue. In regards to multifocality, microdissection of adjacent neoplastic lesions are 
not genetically identical, indicating that multiple foci may emerge and evolve 
independently (15, 16). This phenomena has made PCa research difficult due to the 
difficulty of getting a homogeneous sample that is large enough to study at the molecular 
level.  Fortunately, new techniques such as cell sorting can now be used to isolate specific 
cell populations and many standard techniques have become more sensitive, allowing 
smaller samples to be examined. 
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In order to provide a standard pathological grading system despite the 
heterogeneous nature of PCa, Gleason developed a grading system that is the predominant 
one used by pathologists today.  The data leading to the development of the system was 
collected by studies of the Veterans Administration Cooperative Urological Research 
Group between 1960 and 1975.  The system was developed in the 1970s by Dr. D.F. 
Gleason by blindly correlating tumor histology with patient survival data to determine 
malignancy (17-20). The histological patterns were arranged into five groups (1-5), 
referred to as Gleason grades or patterns. To generate a score, the two most prevalent 
histologic patterns are evaluated and rated as Gleason pattern 1-5, with higher numbers 
representing more aggressive/advanced carcinoma.  These numbers are then added to give 
the Gleason score.  For example, if the most prevalent lesion is a Gleason pattern 4 and 
the second most prevalent is a Gleason pattern 3, then this is a Gleason (4 + 3), or 
Gleason score 7 (21). Each progressive Gleason pattern is represented by cellular and 
architectural changes as depicted in Figure 5.  Gleason score 2-4 is considered low-grade, 
5-7 is intermediate, and 8-10 is a high-grade tumor. 
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Figure 5: The Gleason Grading System.  Pathologic grading system used to 
grade the malignancy of adenocarcinoma. Gleason patterns range from 1, 
representing small, round, normal glands, to a 5, which corresponds to a complete 
loss of glandular architecture.  This figure represents Gleason’s original 
description of glandular architecture of each grade (19). 
 
 Multiple molecular events have been associated with the development of PCa, but 
only several will be described here.  One common early event in PCa progression is the 
loss of a region of chromosome 8p.  This chromosomal loss occurs in approximately 80% 
of tumors as well as in lung and colon cancers (22-24). One region of 8p that is frequently 
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lost early in PCa progression is 8p12-21. The candidate gene for this locus is the 
homeobox gene, Nkx3.1(25).  Nkx3.1 is required for normal prostate differentiation in 
mice, and deletion of one allele is sufficient to cause development of PIN lesions (26) 
(Figure 4).  
 
 Another step in prostate cancer progression occurs with the loss of chromosome 
10q and the tumor suppressor PTEN (Phosphatase and Tensin deleted on chromosome 
10).  Loss of 10q occurs in 50%-80% of prostate tumors and also occurs in breast cancer 
and glioblastoma (27). Loss of this region is thought to occur after 8q since it is observed 
more frequently in carcinoma than in PIN (Figure 4).  PTEN has been implicated in PCa 
due to frequent mutation in PCa cell lines and total loss in other cell lines and xenografts 
(28-30). Loss of PTEN activates the Akt signaling cascade and leads to increased cell 
proliferation (31).  Increased Akt activity has been observed in xenografts as well as 
primary tumors, supporting a role for PTEN in PCa progression (31).  
 
 A third common event in PCa progression that results in carcinoma is the loss of 
chromosome 13q which includes the Retinoblastoma (Rb) tumor suppressor gene.  This 
deletion occurs in at least 50% of prostate tumors (32-34). Rb mutations and loss of 
expression have been observed in localized and advanced carcinomas (35-38) (Figure 4).  
Rb plays an important role in PCa by regulating apoptosis in response to androgens (39-
41). Homozygous deletion of Rb is lethal, but tissue rescue of the Rb null prostates 
revealed dysplasia and invasive carcinoma, which is exacerbated by treatment with 
androgens (27). 
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 Deletion of chromosome 17p is a relatively late-stage event in the progression of 
PCa (42).  This region encodes the well characterized p53 tumor suppressor gene.  p53 
mutations occur infrequently in early invasive carcinoma (43) (44). Mutations of p53 
were identified in advanced carcinomas and metastatic lesions from 
immunohistochemical examination of accumulated protein and by direct mutational 
analyses (Figure 4) (2, 45-47). 
  
 Consistent with the heterogenous nature of PCa, there are many genes that have 
been implicated in the development and progression of PCa. A few of the most studied 
are listed and discussed briefly above.  One simil     arity in the molecular profile of PCa 
exists, however, the importance of the androgen receptor in prostate development and all 
stages of prostate cancer progression.  
 
Androgen Receptor Signaling 
Male steroid hormones 
   The androgen receptor (AR) is part of the superfamily of nuclear receptors 
which traditionally function by binding small cytoplasmic steroid or non-steroid ligands 
that enter cells through diffusion. The type-one receptors (androgen, progesterone, 
estrogen, glucocorticoid, and mineralcorticoid) share functional domains consisting of an 
N-terminal variable domain, a DNA binding domain, a hinge region, and a hormone 
binding domain. Type-one receptors are associated with heat shock proteins when 
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inactive, but upon ligand binding, the heat shock proteins are released, the receptor 
dimerizes, and translocates to the nucleus to activate transcription of target genes.  
 
Prostatic growth and function is regulated predominantly by testicular androgens 
via the androgen receptor, but to a lesser degree by adrenal androgens.  The endocrine 
pathway that ultimately results in synthesis of androgens begins in the hypothalamus. 
Lutenizing Hormone Releasing Hormone (LHRH) is synthesized and released from the 
hypothalamus which stimulates the pituitary to release lutenizing hormone (LH) and 
adrenocorticotropic hormone (ACTH).  LH stimulates the production of testosterone in 
the testis while ACTH stimulates the adrenal glands to synthesize the adrenal androgens 
dihydroepiandrosterone (DHEA), DHEA sulfate, and androstenedione. Both testicular 
and adrenal androgens stimulate the prostate, but testosterone is responsible for the 
majority of effects (Figure 6). Testosterone circulates through the bloodstream where it is 
bound to albumin or sex-hormone binding globulin, or it is free (un-bound). When free 
testosterone reaches the prostate it diffuses across the plasma membrane and is converted 
to the more potent androgen, dihydrotestosterone (DHT), by 5 alpha-reductase. DHT 
binds the androgen receptor, causing a release of heat shock proteins and recruitment of 
co-regulators.  Ligand-binding triggers AR dimerization and phosphorylation followed by 
translocation to the nucleus where AR binds the promoter regions of androgen-regulated 
genes, such as PSA, via an androgen responsive element (ARE) to activate transcription 
(Figure 7). 
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Figure 6: The Male Endocrine Pathway The hypothalamus releases LHRH 
stimulating the pituitary to generate LH and ACTH.  LH stimulates the synthesis 
of testosterone in the testis, while ACTH stimulates production of adrenal 
androgens.  Both testicular and adrenal androgens stimulate the prostate in the 
relative amount shown, 95% and 5% respectively. In addition to stimulating 
prostatic growth, androgens are also part of a negative feedback loop to the 
pituitary and hypothalamus to stop hormone production. Figure adapted from (1).  
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Figure 7: AR Action In the Prostate. Testosterone is released from sex-hormone 
binding globulin (SHBG) and diffuses into an androgen-responsive cell.  Once in 
the cytoplasm, testosterone is converted to DHT, binds AR which causes the 
release of heat shock proteins (HSP).  Ligand binding induces receptor 
dimerization and phosphorylation followed by translocation to the nucleus. 
Nuclear AR binds androgen-responsive elements in the promoter regions of 
androgen-regulated genes, recruits co-regulators such as ARA70, and the general 
transcription apparatus (GTA). Activation of target genes leads to biological 
responses such as production of PSA and promotion of growth and survival. 
Figure from (48). 
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Androgen Receptor in Normal Prostate and Prostate Cancer 
Androgens and the AR are required for development and normal prostate function 
(2, 49-52). The prostates of AR knockout mice do not develop (52) nor do the prostates of 
testicular feminized (Tfm) mice or individuals with inactivating mutations of AR (49, 50, 
53, 54).  Once the prostate develops, androgens  are the primary regulators of epithelial 
cell proliferation and apoptosis (48-50). Androgens promote cell survival and inhibit 
apoptosis (Figure 7) (48, 49).  In the normal prostate, there is a balance between the 
number of cells proliferating and cells undergoing apoptosis resulting in maintenance of 
the size of the gland.  
 
Unlike the genes discussed previously that have been implicated at specific times 
in PCa development and progression, AR is important at all stages (2, 49). AR is required 
for normal prostate function and is expressed in PIN and early carcinoma, however it is 
also expressed in advanced and metastatic carcinoma.  Androgens regulate the 
proliferation rates of epithelial cells, the predominant cell type involved in 
adenocarcinoma, so increased androgen levels or AR activity could result in uncontrolled 
proliferation and cancer. This is one reason that PSA, an androgen-regulated gene, is used 
as a marker for PCa. Another mechanism by which PSA levels are increased in cancer is 
that abnormal ductal structures allow PSA to be secreted into the extra-cellular space, 
rather than prostatic lumens, resulting in increased PSA in the bloodstream (55, 56).   
 
In addition to regulation of PSA, AR regulates a number of other genes through 
numerous interactions with co-activators and co-repressors. Once AR translocates to the 
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nucleus, nuclear AR co-regulators facilitate interactions with DNA and with the general 
transcription initiation complex.   
 
Androgen Deprivation Therapy as a Treatment for PCa 
Prostate cancer is initially dependent upon androgens for growth and survival and 
when androgens are removed, massive apoptosis and tumor regression occurs. This 
observation was made by Huggins and Hodges in 1941 when they reported that castration 
caused prostate cancer regression (57). Huggins performed surgical castration to treat 
prostate cancer, and it was highly effective for a period of time, but eventually the tumors 
recurred independently of androgens. Androgen deprivation therapy (ADT) is still the 
most commonly used therapy for androgen-dependent (AD) prostate cancer (58, 59). 
Today’s physicians rely on chemical castration using mono- or combination therapy. 
Maximum androgen blockade has been initiated when anti-androgens were administered 
along with gonadotropin-releasing hormone (GnRH)  to simultaneously block adrenal as 
well as testicular androgens or with LHRH analogs to block the synthesis of either 
testicular or adrenal androgens (60, 61).  As with physical castration, the tumor initially 
responds to androgen deprivation but will eventually recur as an androgen-independent 
tumor.  The mechanisms behind the progression from androgen-dependency to androgen-
independency have been studied in depth, but appear to vary from patient to patient and 
thus remain difficult to study.  
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Mechanisms for the Development of AIPC 
Feldman and Feldman have complied and discussed additional hypotheses for the 
development of androgen-independent disease (48).  Their hypotheses focus on AR since 
it is likely at the center of the development of androgen-independent prostate cancer 
(AIPC).  Their hypotheses include the hypersensitive AR pathway, the promiscuous AR, 
the outlaw AR, the AR bypass, and lurker cells (Figure 8).  The hypersensitive and 
promiscuous AR hypotheses will be discussed in the most detail as they are closely 
related to this research, but all hypotheses have primary research supporting them which 
is discussed by Feldman (48). 
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Figure 8: Hypotheses for the development of androgen-independent prostate 
cancer. Multiple mechanisms exist for a cancer cell to escape ADT and become 
androgen-independent.  Several of these mechanisms involve AR. A) The 
hypersensitive pathway occurs when AR is amplified or is more sensitive to low 
androgen levels. B) In the promiscuous pathway, AR can be activated by steroids 
or anti-androgens typically due to mutations allowing these agents to act as 
agonists. C) Receptor Tyrosine Kinases (RTKs) can activate AR in the Outlaw 
pathway by phosphorylating AR in the absence of ligand D) The bypass pathway 
does not involve AR, but rather other pro-survival genes like bcl-2 stimulate the 
cell to survive in the absence of AR signaling E) The lurker cell hypothesis relies 
on the possibility that androgen-independent cells always exist in the prostate and 
are selected for by androgen-deprivation therapy (48).   
 21 
 
Hypersensitive AR 
The hypersensitive AR hypothesis is one possible mechanism for prostate cancer 
to circumvent ADT.  If the tumor increases sensitivity to androgens it would be able to 
take advantage of the small amounts of androgens present after ADT. These tumors 
would not strictly be androgen-independent because they would still rely on androgens, 
just in much lower amounts than normal prostate.  For a prostate tumor to become 
hypersensitive to androgens one of two things (or both) must occur. AR must either be 
amplified or become more sensitive to low levels of androgens (Figure 8a). If AR is 
amplified, there is an increase in the percentage of ligand-bound receptor even though 
androgen levels are low. Studies have indicated that approximately 30% of androgen-
independent tumors after ADT have AR amplification, whereas none of them had AR 
gene amplification before androgen-ablation (62-64). 
An alternate mechanism for prostate tumors to become hypersensitive to low-
levels of androgens is through increased AR sensitivity. This mechanism was documented 
in an animal model for PCa where tumor cells exhibited increased expression of AR, 
increased stability, and enhanced nuclear localization of AR (65). These cells were more 
sensitive to DHT than expected: the growth-promoting concentration was 4-fold lower 
than the regular androgen-dependent LNCaP cells. Further, Balk (66) reported that AR 
mRNA levels rose up to 70-fold in metastatic AI compared to primary prostate cancer and 
that AR immunostaining was nuclear in androgen-independent (AI) prostate cancer cells, 
even in patients undergoing ADT/bicalutamide treatment. Examples of increased AR 
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expression and sensitivity demonstrate that these situations occur in vivo and that the 
hypersensitive AR pathway contributes to promotion of androgen-independence. 
 
Promiscuous AR 
A second hypothesis for tumor cells to escape ADT is through a promiscuous AR.  
This hypothesis is based upon the fact that most androgen-independent tumors express 
AR. It seems that many androgen-independent tumors do not arise from loss of androgen 
signaling, but rather from genetic changes that cause divergent activation of the AR 
signaling pathway (67).  These changes are typically missense mutations of AR resulting 
in decreased ligand specificity allowing other non-androgen steroids or androgen-
antagonists to activate AR (Figure 8b).  The rate of AR somatic mutations in PCa has 
been debated in the literature, but seems that most mutations occur in metastatic samples 
(68). Further analysis revealed the mutation rate increased after androgen deprivation (58, 
62, 69-71). It seems logical that gain-of-function mutations would be selected for in order 
to provide a growth advantage. There are many mutations that have been characterized 
and are reviewed thoroughly elsewhere (48, 49). Importantly, most somatic AR mutations 
discovered in AI prostate tissue localize to discrete regions of the receptor and suggest 
that altered androgen signaling provides a potential mechanism for the re-emergence of 
tumor growth during the course of ADT (67). 
 
One of the most well known AR mutations is the T877A substitution mutation 
found in the LNCaP human PCa cell line (72). This mutation allows progestins, estrogens, 
and anti-androgens to act as agonists (48, 73, 74).  Studies of primary prostate tumors 
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revealed that this mutation was present in 6 of 24 metastatic prostate cancer samples, 
indicating that it occurs relatively frequently in AIPC patients (75).  AR mutations that 
allow anti-androgens to gain agonist function could explain the clinically observed 
phenomenon of  “anti-androgen withdrawl syndrome” where patients worsen clinically 
with flutamide treatment, but improve when it is withdrawn (76-78). These patients 
experience rising PSA levels when treated with flutamide and seems to be due to selection 
of cells expressing a promiscuous AR. When flutamide treatment is withdrawn, PSA 
levels decrease as well as other parameters such as acid and alkaline phosphatases. In 
these studies, it seems that flutamide drives selection of cells expressing mutant ARs. The 
T877A mutation was documented in the bone marrow metastases of 5 out of 16 patients 
who had received flutamide treatment (69).  As expected, these cells exhibited growth 
stimulation from flutamide treatment. Tumors in other patients who did not receive 
flutamide treatment had different mutations and did not grow in response to flutamide 
treatment.  This suggests that flutamide treatment provided selective pressure for 
mutations resulting in a promiscuous AR.  
 
A different mechanism whereby flutamide or other anti-androgens could result in 
promiscuous AR activity is through alterations to AR co-regulators.  There are numerous 
co-activators and co-repressors of AR that have been described (49, 79). Studies have 
identified alterations in expression of AR co-regulators when there is no apparent 
mutation of AR (44). An increase in AR activity could be the result of increased 
expression of co-activators, or by decreased expression of co-repressors. Several AR co-
regulators have been specifically linked to advanced and androgen-independent prostate 
 24 
cancers. Two AR co-activators, steroid receptor co-activator 1 (SRC1) and transcriptional 
intermediary factor 2 (TIF2), are over-expressed in several prostate cancer cell lines and 
in some recurrent prostate cancers (80-82). These changes allowed activation of AR at 
physiologic (low) levels of adrenal androgens indicating that these co-activators could 
promote promiscuous AR activity in vivo. Nuclear accumulation of another AR co-
activator, Tat interactive protein, 60kDa (Tip60), was increased in biopsies from patients 
with AIPC (83).  Additionally, Tip60 expression was increased by androgen deprivation 
in the LNCaP and CWR22 xenograft models (82, 83) indicating that Tip60 may be part of 
a family of co-activators that are regulated by ADT to promote development of AIPC. 
The structurally similar AR co-activators, p300 and CBP (CREB binding protein), 
enhance ligand-independent activation of AR in the presence of interleukin 6 (IL-6) (82).  
IL-6 and other cytokines activate multiple signaling cascades, such as the JAK/STAT and 
MAPK pathways that have been identified in the outlaw receptor hypothesis (Figure 8c) 
(48, 82). The role of AR co-repressors in the development of AIPC is less well 
documented, but at least one example has been documented. The AR co-repressor, 
nuclear receptor co-repressor (NCoR), has been shown to differentially repress AR 
activity in the presence of different agonistic and antagonistic ligands. In LNCaP cells 
that express the T877A mutant AR, NCoR was unable to repress the agonistic activity of 
the anti-androgens flutamide and cyproterone acetate (84).  This indicates that AR 
mutations can modify the effectiveness of AR co-repressors.  The expression pattern of 
NCoR and other AR co-repressors has not been evaluated in androgen-independent 
disease, however, decreased expression of NCoR in breast cancer correlated with 
tamoxifen (an ER antagonist) resistance (85). Breast cancer patients that lacked functional 
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NCoR, tamoxifen became an ER agonist and led to the activation of ER responsive genes 
(85).  These examples of nuclear receptor co-activators and co-repressors highlight the 
importance of these proteins in both normal tissues and in the development of hormone 
refractory cancers. 
 
 Finally, there are additional ligand-independent mechanisms involving receptor 
tyrosine kinases, anti-apoptotic genes like bcl-2,  (48, 86, 87) or growth factors such as 
insulin-like growth-factor-1 (IGF-1), keratinocyte growth factor (KGF) and epidermal 
growth factor (EGF) (88, 89) that could alter AR activity in the absence of androgen, 
thereby facilitating progression towards androgen resistant disease (Figure 8C and D). A 
final hypothesis for the development of AIPC is known as the lurker cell. Some believe 
that androgen-independent cells always exist in small numbers in the prostate, potentially 
as prostate stem cells or cancer stem cells, and that ADT provides a growth advantage to 
these cells (Figure 8E) (48) (71).  
 
DJ-1 
Human DJ-1 is located in at 1p36.33-1p36.12 and is composed of 7 exons 
encoding a 20 kilo-Dalton protein (NCBI accession numbers: mRNA D61380, protein 
BAA09603). DJ-1 is a ubiquitous cytoplasmic and nuclear oncogene also known as 
PARK7 (90-92). DJ-1 was initially identified by Nagakubo and colleagues in a yeast two 
hybrid screen for c-myc binding partners (93).  Although a portion of the DJ-1 cDNA 
was identified as a putative c-myc binding protein in this assay, they ultimately 
determined that DJ-1 does not interact with c-myc.  Instead, it was determined to be a 
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false positive because only a small non-coding region of DJ-1 interacted with the c-myc 
fusion protein (93). Although it did not interact with c-myc, the group was still interested 
in the DJ-1 cDNA because it was previously uncharacterized. They determined that 
increased DJ-1 expression is capable of transforming NIH-3T3 cells either alone or, to a 
greater extent, in conjunction with c-myc or H-ras over-expression, thus giving DJ-1 the 
oncogene moniker (93). Since this initial discovery and characterization, DJ-1 has been 
associated with multiple signaling pathways and human diseases, as well as being 
characterized in multiple model systems (90-92, 94-99). 
  
The crystal structure of DJ-1 was determined by several groups, revealing that the 
mature protein exists as an obligate dimer (Figure 9) (100, 101). However, even the 
elucidation of the structure and analysis of the protein sequence was unable to determine 
the function of DJ-1.  There were no known protein domains that were identified in the 
human DJ-1 sequence. Rather, the protein sequence and structure resembled domains 
required for thiamine synthesis and chaperone activity in bacteria (100-102). Since there 
were no exact matches for known protein domains, determination of the crystal structure 
seemed to raise more questions than it answered by providing a potential role for DJ-1 as 
a protein chaperone. 
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Figure 9: Crystal Structure of Human DJ-1. DJ-1 is an obligate dimer. One 
monomer is shown in blue and the second in green. Bottom view is rotated 90 
degrees from the top view. Leucine 166 which is mutated in Parkinson’s disease 
is shown in red.  Figure modified from (100). 
 
 
Since the initial discovery, over-expression of DJ-1 has been associated with a 
number of human diseases including Parkinson’s disease (90, 92) and carcinomas of the 
lung, breast, and prostate  (95, 99).  In Parkinson’s disease research, DJ-1 is referred to as 
PARK7.  Many research groups study the role of DJ-1 in Parkinson’s disease, and have 
discovered multiple functions that may contribute to disease onset and progression.  
Bonifati and associates were among the first to link DJ-1 to autosomal recessive early on-
set Parkinson’s (91) (103). Mapping of the DJ-1 (PARK7) locus in several genetically 
isolated families with this form of Parkinson’s revealed the L166P DJ-1 mutation (103).  
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Bonifati and others determined that this mutation destabilized the protein leading to rapid 
turnover by the proteasome and affected oligomerization and sub-cellular localization 
(91) (90) (104) (105).  Further, Yokota and colleagues determined that down regulation 
of DJ-1 in neuronal cells increased cell death from oxidative stress, ER stress, and 
inhibition of the proteasome, but not by pro-apoptotic stimulation (105). Cell death from 
hydrogen peroxide treatment was rescued by wild-type DJ-1 but not by the L166P mutant 
DJ-1 (105). Additional research in neuroblastoma cell lines (106), Drosophila (107) (108) 
and DJ-1 mutant mice (109) (110) confirmed the role of DJ-1 in oxidative stress and in 
normal function of dopaminergic neurons. Taira and co-workers demonstrated that DJ-1 
expression increased after hydrogen peroxide treatment and that treatment caused a shift 
in the isoelectric point of DJ-1 (106).  Oxidative damage to DJ-1 has been reported in the 
brains of sporadic Parkinson’s disease and Alzheimer’s disease patients (111).  Ten 
isoforms of DJ-1 were identified in Parkinson’s and Alzheimer’s patients with isoelectric 
points ranging from 5.5 to 8.4 (111).   
 
Although mutations in DJ-1 were associated with Parkinson’s disease and 
oxidative stress, the role of DJ-1 in degeneration of dopaminergic neurons was unclear 
until the interaction between DJ-1 and protein-associated splicing factor (PSF) was 
discovered (112).  DJ-1 inhibited the transcriptional-silencing activity of PSF and wild-
type DJ-1 prevented PSF-induced neuronal apoptosis, but mutated DJ-1 was less 
effective (112).  Zhong and colleagues demonstrated that down-regulating DJ-1 
expression using siRNA decreased tyrosine hydroxylase expression (113). Tyrosine 
hydroxylase (TH) is an enzyme critical in the synthesis of dopamine, a pathway targeted 
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in the treatment regimen for Parkinson’s patients. Chromatin immunoprecipitation assays 
determined that DJ-1 bound and transcriptionally-activated the promoter region of TH. 
However, they did not perform gel-shifts to confirm a direct interaction between DJ-1 
and the TH promoter, indicating the interaction could be indirect.  Further, they showed 
that DJ-1 inhibited the sumoylation of PSF and PSF-induced inhibition of TH, providing 
a second mechanism for DJ-1 regulation of TH (113). These results identified a novel 
function for DJ-1 as a transcription factor.  Proteomics suggested that DJ-1 might act a 
transcription factor since it is a dimer, but until recently, there were no known DJ-1 
regulated genes.  
 
In addition to Parkinson’s disease, DJ-1 has been implicated in adenocarcinomas 
of the lung, breast, and prostate (95, 99). Increased DJ-1 expression in lung cancer 
correlates with poor clinical prognosis (95).  Further, increased expression of DJ-1 in 
breast cancer is associated with decreased expression of the tumor suppressor PTEN, 
(95). Despite the oncogenic properties of DJ-1, its functional significance in prostate 
cancer development and progression is not well understood. The importance of PTEN in 
PCa is well documented (27, 30, 114-117) and although it is likely that DJ-1 antagonizes 
PTEN in prostate cancer as in breast cancer, this interaction has not yet been defined in 
prostate. Another  potential link between DJ-1 and prostate cancer was reported by 
Takahashi and colleagues who determined that DJ-1 positively regulates AR (98).   They 
demonstrated that DJ-1 bound the AR-binding-region of PIASx-alpha, a known co-
repressor of AR, thereby releasing and allowing AR to become transcriptionally active 
(98).   Further, Niki and associates demonstrated a second mechanism for activation of 
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AR by DJ-1.  They showed that DJ-1 bound and sequestered DJ-1-Binding-Protein also 
resulting in activation of AR (118). One recent study investigating the role of AR in the 
activation of TH found that DJ-1 inhibited, rather than activated, AR in a neuronal cell 
line, which suggests that the function of DJ-1 likely varies between cell-types (119). 
These data indicated that DJ-1 could function as a co-activator or a co-repressor of AR in 
PCa.  Since the role of AR co-regulators in AIPC has been established, this provided a 
potential role for DJ-1 in androgen-independent disease. Despite the diverse DJ-1 
literature however, there was a lack of research pertaining to the importance of DJ-1 in 
PCa, on the transcriptional regulation of DJ-1, downstream targets, and DJ-1 binding 
proteins.   
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Figure 10: DJ-1 Indirectly Activates AR. DJ-1 binds and inhibits PIASx-alpha 
preventing it from binding AR. DJ-1 also binds DJ-1 Binding Protein (DJBP) and 
a multi-protein HDAC co-repressor complex resulting in AR activation. Figure 
modified from (98).  
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Construction of Viral Constructs 
 The androgen responsive 5'-flanking region [(-244/-96)(-286/+28) bp] of the rat 
PB gene designated ARR2PB was linked to the chloramphenicol acetyl transferase (CAT) 
reporter gene (120) and subcloned into the XhoI/BglII restriction sites of pAdBN 
(AdenoQuest Quantum Biotechnology, Montreal, Canada) to create pPB-CAT/Ad. Viral 
particles were generated in 293 cells according to the manufacturer’s protocol and titrated 
in LNCaP cells. Only those clones which resulted in high levels of CAT gene expression 
in response to androgen treatment were selected and amplified for the HPE cell TIGR 
assay. The negative control plasmid contained a promoterless CAT gene (pCAT/Ad). 
 
 To generate DJ-1 shRNA, appropriate oligos were designed using the online tools 
at www.Genscript.com.  Briefly, the full-length human DJ-1 cDNA sequence was 
inserted into the online system which generates several potential hairpin sequences using 
a proprietary algorithim.  One of these sequences was chosen by comparing the generated 
sequences to published reports for known DJ-1 siRNA/shRNA sequences that had been 
effective.  Once an oligo was chosen, a control shRNA sequenced was generated by 
scrambling the DJ-1 shRNA sequence to generate a non-targeting shRNA. (performed by 
Genscript online tools) The control sequence was checked for potential off-target effects 
by BLASTing the sequence against the human genome (performed through Genscript 
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website). The oligonucleotides contained overhangs complimentary to BamHI and XhoI 
sites to be used to clone the oligos into pRNATi/Lenti plasmid (Genescript).  Oligos were 
ordered from www.IDT.com and PAGE purified.  To anneal the oligos and generate 
double-stranded products, 1ug of each oligo was combined in a total volume of 20 ul IX 
SSC and heated at 95°C for 10 minutes and then incubated at room-temperature for one 
hour. The annealed oligos were then cloned into the pRNATi/Lenti plasmid (Genescript).  
Oligos for DJ-1 shRNA were: top strand – 5’- 
GATCCCGTCTCAGAGTAGGTGTAATGACTTGAT-3’ and bottom strand – 5’- 
TCGAGTTGGAAAAAATCTCAGAGTAGGTGTAAT-3’.  Scrambled (non-targeting) 
control shRNA oligos were: top strand – 5’-
GATCCCGTACCAATACTACCATTCGAGTTTGAT-3’  and bottom strand – 5’-
TCGAGTTGGAAAAAAGTACCAATACTACCATTC-3’.   Plasmids were transfected 
into 293FT cells (Invitrogen) to generate lentiviral particles according to manufacturer’s 
protocols.  Viral supernatant was used to infect LNCaP-TET-ON cells which were 
obtained from Dr. Renjie Jin in the Matusik laboratory at Vanderbilt.  Infected cells were 
isolated by FACS sorting for GFP positive cells, and grown to confluency.  DJ-1 was 
knocked down by treating cells with the indicated dose of doxycycline for 24 hours. 
 
HPE Cell Culture 
 A total of 40, two to four millimeter (mm3) specimens were obtained from radical 
retropubic prostatectomy, with 30 specimens composed of histologically normal, non-
tumor tissue and 10 specimens composed of 5 to 95 % PCa (Gleason Score 3+3). Since 
one or two specimens were obtained per patient, the 40 specimens represent 28 
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individuals. Two to four mm3 prostatic tissue fragments were just sufficient to generate 
HPE cells to perform the bioassay and isolate protein and RNA for a limited number of 
Westerns and RT-PCR reactions presented in this study. Primary HPE cells were isolated 
and cultured according to the method of Hayward and colleagues (121). Briefly, punch 
biopsies of prostate tissue were minced, tissue fragments were plated on Primaria plates 
(Falcon, Phoenix, AR) and HPE cells were cultured in epithelial cell selective medium 
(RPMI 1640 medium supplemented with 2.5 % charcoal stripped, heat-inactivated FBS, 
20 mM HEPES buffer, 100 units/ml penicillin, 100 µg/ml streptomycin, 0.25 µg/ml 
amphotericin B, 50 µg/ml gentamycin, 56 µg/ml bovine pituitary extract, 1x insulin-
transferrin-selenium, 10 ng/ml epidermal growth factor, and 50 ng/ml cholera toxin) and 
maintained in 5 % CO2 at 37o C. The medium was changed every 2 to 4 days and HPE 
cells from individual prostatectomy specimens were maintained and passaged for a 
maximum of 4 passages. 
 
TIGR (transiently infected gene reporter) assay 
 The LNCaP and PC-3 human prostate cancer cell lines were purchased from the 
American Type Culture Collection (Rockville, MD) and served as controls in this study. 
Cells were plated in 24-well plates at a density of 105cells/well and upon reaching 80% 
confluence, were infected with 108 plaque forming units (pfu) adenoviral particles 
containing pCAT/Ad or pPB-CAT/Ad and treated with anti-androgen (flutamide, 10-5 M) 
or androgen (10-8 M R1881) with/without flutamide (10-5 M) in the presence of 2.5% 
charcoal-stripped fetal bovine serum. The concentration of 10-5 M flutamide was selected 
since it inhibited greater than 99.5% of androgen-induced activity in LNCaP cells                                       
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. Forty eight hours later, cells were harvested, lysed in passive lysis buffer (Promega, 
Madison, WI), protein concentrations were determined using the Bio-Rad Protein Assay 
and 20 µg protein per sample were used to determine CAT activity as described 
previously (122). At least three separate experiments (each treatment in triplicate) were 
carried out. 
 
 The length of time required to transfect primary HPE cells was determined by 
utilizing adenoviral particles containing pCMV-EGFP. HPE cells were faintly green 3 
days post infection and EGFP expression increased up to 4 days when intensity stabilized 
and did not change thereafter (data not shown). Therefore, 4 days post infection was 
selected as the time point to harvest HPE cells and determine reporter gene activity. The 
TIGR assay was carried out as described above. Since prostatectomy material was rate 
limiting (only two to four mm3), each of the 40 assays was performed one to two times 
and each treatment group was analyzed in quadruplicate.  
  
Western Blot Analysis 
 HPE cell proteins were isolated according to TRI REAGENT™ protocol (Sigma, 
St. Louis, MO). Protein concentrations were determined by the Bradford Protein Assay 
(Bio-Rad). Thirty micrograms of total protein were separated on precast 4-12 % 
NuPAGE® Novex polyacrylamide gels (Invitrogen, Carlsbad, CA) and transferred onto 
Hybond™ ECL™ Nitrocellulose membranes (Amersham Pharmacia Biotech, Uppsala, 
Sweden). Only 50 ng LNCaP protein was loaded per lane, since LNCaP AR 
concentrations were higher (see Figure 4C, real-time RT-PCR data) and did not facilitate 
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the longer exposure time required to visualize the HPE AR. After blocking with 5 % Skim 
Milk (BD, Sparks, MD) membranes were incubated with a 1:1000 dilution of rabbit 
polyclonal anti-AR antibody (Santa Cruz Biotechnology, Santa Cruz, CA), washed and 
subjected to 1:10,000 dilution of horseradish peroxidase linked anti-rabbit IgG 
(Amersham Pharmacia Biotech, Uppsala, Sweden). Proteins were visualized by ECLplus 
Solution (Amersham Pharmacia Biotech, Uppsala, Sweden) and exposure to Hyperfilm™ 
ECL™ (Amersham Pharmacia Biotech, Uppsala, Sweden) for 1 to 2 minutes. For 
subsequent β-actin detection, the membrane was stripped [100 mM 2-mercaptoethanol, 2 
% SDS, 62.5 mM Tris-HCl for 30 min at 70oC], washed, blocked, and subjected to 
immunodetection as outlined above utilizing rabbit polyclonal anti-actin (1:200 dilution) 
as primary antibody (Santa Cruz Biotechnology, Santa Cruz, CA). 
 
 For DJ-1 analysis, 20 µg total protein was separated on precast Ready gel 4-20% 
polyacrylamide (BioRad) and transferred onto PVDF membrane (BioRad). Nonspecific 
binding and washes were performed as described above and membranes were incubated 
with 0.5 µg/µl of mouse anti-DJ-1 antibody (Stressgen Biotechnologies Corp., San Diego, 
CA) and simultaneously probed with 1:5,000 dilution of mouse anti-beta-actin antibody 
(Sigma), washed, and then incubated with 1:10,000 dilution of horseradish peroxidase 
linked anti-mouse IgG (Amersham Pharmacia Biotech, Uppsala, Sweden). Proteins were 
visualized as described above.  
 
For Western analysis in Chapter IV the following antibodies were used:  1:1000 
dilution of goat anti-DJ-1 antibody was used  (Abcam, Cambridge, MA), 1:1000 dilution 
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of rabbit anti-AR (N-20) antibody (Santa Cruz Biotechnology, Santa Cruz, CA), 1:5000 
dilution mouse anti-GAPDH (Imgenex, San Diego, CA), 1:1000 dilution mouse anti-Rho 
A (Santa Cruz Biotechnology, Santa Cruz, CA), 1:1000 dilution (in 2% BSA) of mouse 
anti-Histone H1 (Abcam, Cambridge, MA).  Membranes were washed and subjected to 
1:5000 dilution of horseradish peroxidase (HRP) linked anti-goat IgG (Santa Cruz 
Biotechnology, Santa Cruz, CA), 1:10,000 dilution of HRP-anti-rabbit IgG, or 1:10,000 
HRP-anti-mouse IgG (Amersham Pharmacia Biotech, Uppsala, Sweden). Proteins were 
visualized as described above. 
 
Reverse transcriptase-polymerase chain reaction (RT-PCR) 
 Total cellular RNA from primary HPE cultures, LNCaP, and DU-145 cell lines 
was extracted using TRI® Reagent (Sigma, St. Louis, MO) according to the 
manufacturer’s instructions. Two µg total RNA for all cell lines was utilized to generate 
cDNA (RT-PCR Access System, Promega, Madison, WI) and the cDNA was subjected to 
PCR analysis with gene specific primers for AR, PSA, and 18S for 35 cycles as indicated 
below. The PCR products were analyzed by electrophoresis on 1.5% agarose gels. 
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Table 1: RT-PCR primer pairs.  Forward primer is listed on top, followed by 
reverse primer. All primer pairs target human sequence unless otherwise specified. 
 
Gene 
Name Primers 
Product 
Length 
(bp) 
Annealing 
Temp. 
(OC) 
AR 5’-AGCCCCACTGAGGAGACAACC-3’ 5’-ATCAGGGGCGAAGTAGAGCAT-3’ 350 60 
PSA 5’-CCTCACACCTAAGGACAAAGG-3’ 5’-CATTGAACCAGAGGAGTTCTTG-3’ 414 60 
18S 5’-CAAGAACGAAAGTCGGAGGTTC-3’ 5’-CTGTGATGCCCTTAGATGTCC-3’ 488 60 
DJ-1 
(DJ1Cf) 5’-ATGGCTTCAAAAAGAGCTCTGG-3’ 
(DJ1CR) human 5’-CTAGTCTTTAAGAACAAGTGGA-3’ 
(mDJ1R) mouse 5’-CTAGTCTTTGAGAACAAGCGGT -3’ 
569 56 
FKBP9 5’-GTACTTCTGATGGATATTTGG-3’ 5’-GTTGTGGAAGTCGATCACAT-3’ 670 50 
P-cadherin 5’-GATGCCATCTACACCTACAAT-3’ 5-CATGATAAGGTAGGTGGCAC-3’ 380 50 
PLOD-1 5’-TTCAAGCGCTCAGCTCAGTTC-3’ 5—CTTGAGCACGACCTCATCCA-3’ 530 54 
 
 
Real-time RT-PCR analysis 
 AR concentrations in cultured HPE cells were determined by real-time RT-PCR, 
utilizing 2 µg HPE total RNA to generate cDNA which was subsequently used in PCR 
reactions with the primers described above [icycler iQ Real-Time PCR Detection System 
(Bio-Rad, Hercules, CA)]. LNCaP cells (2 µg total RNA) served as a positive control. 
The AR standard curve was generated using serial dilutions of the human pSVAR0 
expression vector. The human 18S gene was subcloned into pGEM-T easy (Promega, 
Madison, WI) and served as an internal standard. PCR amplification was performed using 
SYBR Green PCR Core Reagent (Applied Biosystems, Foster City, CA), followed by 
analysis of melting curves to validate the real-time RT-PCR data and agarose gel 
electrophoresis of an aliquot from each RT-PCR product to monitor purity of the specific 
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RT-PCR product. AR concentrations (in µM) were determined and standardized to the 
18S product from the same sample.   
DJ-1 expression in CD-1 and 12T-7f mice was determined using 2ug total pooled 
RNA that was used for generation of cDNA as described (123). cDNA was used for 
subsequent real-time RT-PCR using DJ-1 primers:  for mouse DJ-1 amplification, DJ1CF 
primer + mDJ1-R primers were used, while human DJ-1 is amplified with DJ1CF and 
DJ1CR primers. DJ-1 expression was normalized to 18S rRNA as described above.  The 
standard curve was generated using serial dilutions of full-length human DJ-1-TEasy 
plasmid.   
 
AR mutational analysis 
 The HPE AR was screened for potential somatic mutations. PCR amplification of 
six targeted areas in which most of the prostate cancer somatic mutations co-localize [2 in 
the AR-NTD [aa 54-92; 253-282;] and 4 in the AR-HBD [aa 654-689; 688-721; 723-738; 
867-917] was performed on genomic DNA. The following primer pairs were designed to 
encompass the targeted areas. 
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Table 2: Primers Used in AR Mutational Analysis Forward primer listed on top, 
followed by reverse primer. Exonic/Intronic location and amino acids are given. 
 
Target Name Primers Primer Location Amino Acid Range 
Annealing 
Temp. (OC) 
AR-I 5' CTT TCC AGA ATC TGT TCC AGA G 3' 5' CCT CAT CCA GGA CCA GGT AGC C 3' 
Exon 
Exon Leu54 to Ser92 55 
AR-II 5' GTG TGG AGG CGT TGG AGC AT 3' 5' GAA CCT TTG CAT TCG GCC AA 3' 
Exon 
Exon Leu253 to Pro282 48 
AR-IV 5' ACC AGC CCC ACT GAG GAG ACA A 3' 5' TGC AAA GGA GTC GGG CTG GT 3' 
Exon 
Exon Thr654 to Asn689 62 
AR-V4 5' AGG TGT AGT GTG TGC TGG AC 3' 5' CCA CTT CCC TTT TCC TTA CC 3' 
Exon 
Intron Asp688 to Pro721 53 
AR-V5 5' TAC CCA GAC TGA CCA CTG CC 3' 5' AAA CAC CAT GAG CCC CAT CC 3' 
Intron 
Exon Phe723 to Ser738 61 
AR-VI 5' GAG GCC ACC TCC TTG TCA ACC CTG 3' 5' GGG GTG GGG AAA TAG GGT TT 3' 
Intron 
Intron Ile867 to End917 53 
 
 
 
The PCR products were sequenced utilizing an Applied Biosystems ABI Prism 377 DNA 
Sequencer at the Norris Cancer Center Genomics Core facility (UCS/Norris, LA) and the 
resulting data aligned to the AR sequence (124) using Sequence Navigator software. 
  
Electron microscopy 
 HPE cells cultured in 6 well culture plates were fixed in 2% glutaraldehyde in 
PBS for 5 minutes at room temperature. Cells were scraped, pelleted and further fixed for 
60 minutes at room temperature. The pellets were processed for electron microscopy by 
standard techniques and thin and semi-thin sections were cut and stained with uranyl 
acetate and lead citrate and photographed on a Joel X100 microscope. 
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Two-Dimensional gel electrophoresis and mass spectrometry 
 Samples were individually solubilized in lysis buffer (7M urea, 2M thiourea, 4% 
CHAPS, 30 mM Tris, 5 mM magnesium acetate) prior to labeling with 200 picomoles of 
either Cy2, Cy3 or Cy5 (Amersham Biosciences, Piscataway, NJ) for 30 min on ice in the 
dark. Reactions were quenched with 2 µl of 10 mM lysine for 10 min on ice in the dark, 
combined and added to an equal volume of 2x rehydration buffer (7M urea, 2M thiourea, 
4% CHAPS, 4 mg/mL DTT) supplemented with 0.5% IPG (Immobilized pH gradient) 
buffer 4-7. Combined samples (Cy2/3/5) were co-resolved by standard 2D gel 
electrophoresis using an IPGphor first-dimension isoelectric focusing unit and 24 cm 4-7 
immobilized pH gradient (IPG) strips (Amersham Biosciences, Piscataway, NJ), followed 
by second-dimension 12% SDS-PAGE using an Ettan DALT 12 unit (Amersham 
Biosciences, Piscataway, NJ). The samples were reduced and alkylated with 1% DTT and 
2.5% iodoacetamide in equilibration buffer (6M Urea, 30% glycerol, 2% SDS, 50mM 
Tris pH 8.8) between the first- and second-dimensional separations. Second-dimension 
SDS PAGE gels were hand-cast using low-fluorescence glass plates, with one glass plate 
pre-silanized (bind-silane, Amersham Biosciences, Piscataway, NJ) to affix the 
polymerized gel to only one of the glass plates.  
 
  CyDye-specific images were acquired using mutually-exclusive 
excitation/emission wavelengths using 2D 2920 Master Imager (Amersham Biosciences, 
Piscataway, NJ). Individual protein spot-features were co-detected and analyzed using 
DeCyder Differential In-gel Analysis software (Amersham Biosciences, Piscataway, NJ), 
where individual spot volume ratios were calculated for each protein-pairs. Two standard 
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deviations of the mean, calculated from a modeled normal distribution of all spot volume 
ratios, was used to identify those protein spot features that exhibited significant 
abundance changes within the 95th percent confidence level. 
 
  The 2D gels were subsequently stained with Sypro Ruby (Molecular Probes, 
Eugene, OR) according to the manufacturer’s instructions, to allow for accurate robotic 
protein excision. Proteins of interest were robotically excised and processed for digestion 
in-gel with trypsin protease (Promega) using Ettan Spot Picker and Digester workstations 
(Amersham Biosciences, Piscataway, NJ) Peptides were reconstituted in 10 µl of 0.1% 
triflouroacetic acid, and manually de-salted/concentrated into 2 µl of 60% acetonitrile, 
0.1% triflouroacetµic acid using C18 ziptip pipette tips (Millipore, Billerica, MA). The 
peptide eluate (0.5 µl) was applied to a sample target and overlaid with 0.5 µl of α-cyano 
4-hydroxycinnamic acid matrix (10 mg/ml in 60% acetonitrile, 0.1% triflouroacetic acid). 
Matrix-assisted laser desorption/ionization, time-of-flight (MALDI-TOF) mass 
spectrometry was performed on a Voyager 4700 (Applied Biosystems, Foster City, CA). 
Peptide mass maps were acquired in reflectron mode averaging 2000 laser shots per 
spectrum, and internally calibrated to within 20 ppm mass accuracy using trypsin 
autolytic peptides (m/z = 842.51, 1045.56 and 2211.10). Ions specific for each sample 
(discrete from background and trypsin-derived ions) were used to interrogate human 
sequences entered in the SWISS-PROT and NCBInr databases using the MASCOT 
(www.matrixscience.com) and ProFound (prowl.rockefeller.edu) database search 
algorithms, respectively. Protein identifications from MALDI-TOF peptide mass maps 
are based on the masses of the tryptic peptides (125-127). Searches were performed 
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without constraining protein molecular weight or isoelectric point, and allowed for 
carbamidomethylation of cysteine, partial oxidation of methionine residues, and one 
missed trypsin cleavage.  
 
Northern Blot Analysis 
 LNCaP cells were cultured in normal growth media (RPMI 1640, 10% FBS, 1X 
penicillin/streptomycin, 0.25% glucose, 1mM Na Pyruvate) until 70% confluent when 
media was changed for growth media containing 10% charcoal-stripped FBS for 
overnight. The next day, cells were treated with 10-8M DHT, 10-5M OH-Flutamide, 10-5M 
Casodex, or ethanol (vehicle control) for the following times: 15 minutes, 30 minutes, 45 
minutes, 1, 2, 4, 8, 12, 16, or 24 hours. Cells were harvested in 1 ml Trizol (Invitrogen) 
and RNA was extracted following manufacturer’s instructions. 20 micrograms of total 
RNA was loaded per lane on a 1% formaldehyde-agarose gel and transferred overnight in 
6X SSC by upward capillary transfer to positively charged nylon membrane. For probe 
synthesis, full length human DJ-1 cDNA was cloned into pGEM-Teasy (Promega). The 
plasmid was linearized with Sac II (NEB) and single stranded antisense RNA probes for 
DJ-1 were transcribed in vitro using Megascript SP6 RNA Polymerase transcription kit 
(Ambion). To label the probe, the reaction was supplemented with 3000 Ci/mmol alpha-
P32-UTP (Amersham Biosciences). The membrane was hybridized overnight with 106 
counts in buffer containing (0.2M NaPO4, 7% SDS, 100 µg/ml sheared herring sperm 
DNA, and 2X Denhardt’s solution (Sigma)) at 65 degrees. The membrane was washed in 
2X SSC, 1X SSC, and 0.5X SSC containing 0.1%SDS and then exposed overnight to a 
phosphor imager.  
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Cyclohexamide Assay 
 LNCaP cells were cultured to 70-80% confluency in normal growth media as 
described above when media was changed to media containing 10% charcoal stripped 
FBS for overnight after which cells were pretreated with one of the following: 10-8M 
DHT, 10-5M OH-Flutamide, or an equal volume of 100% ethanol (vehicle control) 30 
minutes before the addition of 75 µg/ml cycloheximide for the following times: 24 hours, 
48 hours, and 72 hours. Cells were harvested in 300 µl of lysis buffer (25mM HEPES [pH 
7.5], 5 mM MgCl2, 300 mM NaCl, 1 mM EDTA, 0.2 mM EGTA, 1mM DTT, 10% 
glycerol, 1% TritonX 100, 0.1% Na-deoxycholate, 0.1% SDS, 20 mM p-
nitrophenylphosphate, 20 mM β-glycerolphosphate, 2 mM Na-pyrophosphate, 1 mM 
PMSF, 10 µg/ml Aprotinin, and 10 µg/ml Leupeptin), briefly sonicated, and clarified by 
centrifugation. Twenty µg total protein was separated on a denaturing 12% acrylamide 
gel, transferred to PVDF membrane and DJ-1 and GAPDH were visualized as described 
above. 
 
Yeast Two-Hybrid Assay  
Yeast Two-Hybrid Assay was performed using the Matchmaker System 
(Clontech, Mountain View, CA) following manufacturer’s protocols. A cDNA library 
was generated from primary Human Prostate Epithelial cells that exhibited AR activation 
via TIGR assay (128) were harvested, total RNA was extracted (Trizol, Invitrogen, 
Carlsbad, CA) and used for reverse-transcriptase PCR using Oligo dT primers. cDNAs 
were cloned into the pGADT7 plasmid (Clontech, Mountain View, CA) where they were 
expressed as fusion proteins to the GAL4 Activation Domain. For the bait protein, full-
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length human DJ-1 cDNA was cloned into the pGBKT7 plasmid and expressed as a 
fusion to GAL4 DNA Binding Domain. Plasmids were transformed into AH109 yeast 
strain and positive clones were selected on high stringency dropout plates (-Leu/-Trp/-
His/-Ade) containing X-alpha-Galactose. Plasmid DNA was extracted, transformed into 
DH5-alpha competent E. Coli, and sequenced using T7 promoter. 
 
Cell Culture and Transfection of LNCaP and LAPC4 Cell Lines  
The LNCaP human prostate carcinoma cell line was obtained from American 
Type Culture Collection (Manassas, VA).  LNCaP cells were cultured as described (128).  
The LAPC4 human prostate carcinoma cell line was a gift from Dr. Charles Sawyers 
(Memorial Sloan-Kettering Cancer Center, New York).  LAPC4 cells were cultured in 
IMDM media (Gibco, Carlsbad, CA) containing 10% FBS,  2 mM L-Glutamine, with 1X 
Penicillin/Streptomycin.  
 
Immunoprecipitation 
Cells were lysed in 300 µl cold lysis buffer (1% Triton X-100, 150 mM NaCl, 10 
mM NaHPO4 pH 7.2, 5 mM NaF, 2 mM EDTA, 1X HALT Protease Inhibitor cocktail 
(Pierce Biotechnology. Rockford, IL)) in the cold room and allowed to rock for 15-20 
minutes. Lysates were cleared by centrifugation and 400-500 micrograms of total protein 
was immunoprecipitated overnight at 4°C using 10µg rabbit anti-AR antibody or 5µg 
mouse anti-HA antibody (Santa Cruz Biotechnology, Santa Cruz, CA).  Complexes were 
pulled down using ImmunoPureTM Immobilized Protein G beads (Pierce Biotechnology, 
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Rockford, IL) Immunoprecipitates were washed 4 times in 1X PBS, re-suspended in 1X 
Lammeli buffer and subjected Western analysis. 
 
Luciferase Assays 
LAPC4 cells were plated in 24-well plates (Falcon, Phoenix, AZ) and allowed to 
attach overnight. Cells were transfected with androgen-responsive luciferase reporter, 
ARR2PB-luciferase. Firefly luciferase is driven by the androgen-responsive region of the 
rat probasin promoter similar to the ARR2PB-CAT reporter (128, 129). Media was 
changed to IMDM containing 10% charcoal-stripped FBS, 2 mM L-Glutamine, 1X 
Penicilin/Streptomycin, and supplemented with 10-9M DHT. 48 hours post-transfection, 
cells were lysed in 1X Passive Lysis Buffer (Promega, Madison, WI) and frozen at -80°C 
until subsequent luciferase assay.  Lysate was cleared by centrifugation and protein 
concentration was determined as described above. 20µl of lysate was loaded into 96-well 
plates (Corning, Corning, NY) and luciferase activity was determined using the 
Luciferase Assay System (Promega, Madison, WI) and a LUMIstar luminometer (BMG 
Lab. Technologies, Inc. Durham, NC). Firefly luciferase activity was normalized to 
protein concentration and expressed as fold change over non-transfected controls.  Each 
bar represents the mean of at least three replicates +/- SEM and each experiment was 
repeated at least twice. 
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Nuclear and Cytoplasmic Extracts 
Cells were plated in 6-well plates (Falcon, Phoenix, AZ) and allowed to attach 
overnight.  On the second day, cells were washed in Hank’s buffer and changed to media 
containing 10% charcoal-stripped FBS.  On the third day, media was again replaced for 
fresh media containing 10% charcoal-stripped FBS and the following treatments: ethanol 
(vehicle control), 10-8M DHT (LNCaP), 10-9M DHT (LAPC4), 10-5M OH-flutamide 
(LNCaP), 10-6M OH-flutamide (LAPC4), 10-5M bicalutamide (LNCaP), or 10-6M 
bicalutamide (LAPC4). Optimal concentrations of androgens and anti-androgens for 
LNCaP cells were experimentally determined previously (128) while concentrations for 
LAPC4 cells were communicated from Dr. Sawyers’ lab.  24 hours after treatment, cells 
were  harvested by trypsinization, washed in PBS, and lysed for cytoplasmic and nuclear 
fractions using the NEPER Kit and HALT Protease Inhibitors according to 
manufacturer’s protocol.  
 
Immunofluorescence and Confocal Microscopy 
Prostate specimen fragments were formalin-fixed and paraffin-blocked. Tissue 
sections (5 microns) were deparaffinized and antigen retrieval was performed by 
immersing the slides in citric buffer (pH 6.0), microwaving for 10 min and allowing the 
slides to cool to room temperature in the buffer. The slides were washed twice in distilled 
water prior to immunohistochemical analysis. For cultured HPE cells, the cells were 
harvested by trypsinization and allowed to attach to glass slides (VWR) overnight at 
37°C. Slides were fixed in 4% paraformaldehyde/phosphate buffed saline (PBS) for 
15 min, washed three times in PBS, permeabilized on ice in PBS + 0.1% Triton X-100 for 
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5 min and blocked in PBS with 3% BSA and 3% donkey serum for 30 min at room 
temperature. Slides were incubated with rabbit polyclonal antibody against human p63 
(Santa Cruz), mouse monoclonal antibody against human CK8 or CK18 (Sigma), rabbit 
polyclonal antibody against human AR, goat polyclonal antibody against human PSA 
(Santa Cruz), monoclonal mouse anti-human Adipophilin or CD59 for 1 h at room 
temperature, and subsequently incubated with Alexa Fluor 594 and/or Alexa Fluor 488-
conjugated donkey anti-rabbit, mouse or goat secondary antibody (Molecular Probes) for 
1 h at room temperature. The slides were washed in PBS and mounted using Vectashield 
mounting medium containing 4,6-diamidino-2-phenylindole (DAPI) to counter-stain 
nuclei (Vector Laboratories). Images were captured with a Zeiss fluorescence microscope 
equipped with a digital camera. To demonstrate specificity of staining, either the primary 
antisera or secondary antibodies were omitted from control slides.  
 
LNCaP and LAPC4 cells were harvested by trypsinization and allowed to attach 
to glass chamber slides (Lab-Tek Products Naperville, IL) overnight at 37°C. Cells were 
treated as described in nuclear/cytoplasmic extract section. 24 hours after treatment, 
slides were fixed, permeabilized, and blocked as described above. Slides were incubated 
with 1:1000 dilution anti-DJ-1, 1:500 dilution (for LNCaP) or 1:100 dilution (for 
LAPC4) anti-AR, and 1:2500 dilution of mouse anti-SC-35 (Sigma, St. Louis, MO) 
antibody overnight at 4°C, and subsequently incubated with Alexa Fluor 594-conjugated 
donkey anti-rabbit, Alexa Fluor 488-conjugated donkey anti-goat, and Alexa Fluor 654-
conjugated donkey anti-mouse secondary antibody (Molecular Probes, Eugene, OR) for 
1 h at room temperature. The slides were washed in PBS and mounted in 50% glycerol 
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and imaged with a Zeiss LSM510 Meta Laser Scanning microscope.   Stacks were 
acquired with LSM510 software, Z-projections and merged images were made with NIH 
ImageJ.  All confocal images were acquired with a Plan-Apochromat 63x/1.4 oil DIC 
objective at the following settings: wavelength 488nm 5%, 543 nm 37%, 633 nm 10%; 
filters: Ch2-1: BP5050-550, Ch3-2:BP 560-615; and ChS1-3: 649-756 with a pinhole of 
281 micrometers. Images have identical microscope settings between treatment groups. 
Image brightness/contrast was not altered between treatment groups so intensity 
comparisons could be made. Quantification and images of co-localization were obtained 
using MetamorphTM software. 
 
Human Tissue Arrays and Immunohistochemistry 
Tissue microarrays (TMA) were generated using H&E slides from 112 radical 
prostatectomy specimens (from 1989 to 2003) obtained from the Vancouver General 
Hospital.  Benign and cancer sites were identified and marked in donor paraffin blocks 
using matching H&E reference slides.  TMA was constructed using a manual tissue 
micro-arrayer (Beecher Instruments, Silver Springs, MD).  Each marked block for benign 
and cancer was sampled 4 times with a core diameter of 0.6 mm arrayed in rectangular 
pattern with 1 mm between the centers of each core creating a quadruplicate TMA layout 
and ordered by histopathology and tumor Gleason grade.  The Gleason TMA contains 
336 tissue cores representing 84 patients.  The second TMA represents patients who 
received either no androgen deprivation therapy (ADT), less than 3 months ADT, 3-6 
months ADT, or more than 6 months ADT.  These patients received with mono- or 
combination therapy with the LHRH antagonists Lupron or Zoladex, and the anti-
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androgens flutamide or cyproterone acetate. The second TMA was generated in a similar 
manner and tissue cores were arranged based upon treatment group.  The ADT TMA 
contains 294 cores representing 98 patients.  DJ-1 immunohostochemistry was performed 
using 1:1000 dilution of goat anti-DJ-1 antibody (Abcam, Cambridge, MA) and 
visualized using DAB and standard techniques. 
 
Hormones 
DHT is commercially available and was purchased from Sigma.  OH-flutamide 
was purchased from LKT Laboratories, Inc. (St. Paul, MN). bicalutamide was provided 
by Astrazeneca, Inc. (Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK). 
 
 
Plasmids and siRNA 
DJ-1 was  cloned into pCruz-HA plasmid (Santa Cruz Biotechnology, Santa Cruz, 
CA) and transiently transfected into LAPC4 cells using Lipofectamine 2000 and 
following manufacturer’s protocol (Invitrogen, Carlsbad, CA).  Cells expressing N-
terminal HA-tagged DJ-1 were selected using 400 µg/ml G418.  Western Blot confirmed 
expression of tagged DJ-1. To knockdown DJ-1 expression, pooled  siGENOME 
SMARTpool siRNAs (Dharmacon catalog #M-005984-00 Lafayette, CO) directed 
against DJ-1 were transfected (200 picomoles/well of 6 well plate) into LAPC4 cells 
using Lipofectamie 2000.  Cells were harvested 48 hours post-transfection for Western 
Blot or luciferase assay.  To ensure specificity of the chosen siRNA pool, a pool of 
nonspecific siRNAs  (200 picomoles/well of 6 well plate) was used as a control 
(Dharmacon Non-targeting  siRNA #1 catalog # D-001210-01).   
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Statistical Analysis 
 For the cell lines, statistical analyses were performed on at least three separate 
experiments (in triplicate or quadruplicate) and represent the mean +/- SD. For HPE CAT 
assays, measurements were carried out in quadruplicate and represent the mean +/- SD. 
These assays were performed up to two times per specimen depending on the size of the 
prostatectomy specimen acquired from Surgical Pathology.  
 For luciferase assays and real-time RT-PCR, bars represent mean values +/- SEM.  
P-values were determined using Student’s t-test and each experiment was repeated at 
least twice. 
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CHAPTER III  
 
 
ANDROGEN AND ANTI-ANDROGEN TREATMENT MODULATES AR 
ACTIVITY AND DJ-1 STABILITY 
 
Introduction 
 Currently, there are no markers that identify patients who may exhibit adverse 
responses to ADT. The agonistic effects of anti-androgens have been extensively studied 
in prostate cancer cell lines such as LNCaP and DU-145 as well as in cell lines derived 
from African green monkey kidney such as COS-1, COS-7 and CV-1. However, these 
cell lines are far removed from the patient and do not represent the early changes that 
occur while the disease is primarily organ confined. The TIGR (Transiently Infected Gene 
Reporter) assay was specifically developed to analyze the effects of androgen and anti-
androgen treatment on the endogenous AR by culturing primary HPE cells directly from 
patient biopsy specimens. 
 
 Primary HPE cells were grown out of biopsy specimens from radical retropubic 
prostatectomy samples as described (121, 128). Once luminal epithelial cells were 
isolated, they were infected with an androgen-responsive reporter gene. The androgen-
responsive 5'-flanking region [(-244/-96)(-286/+28) bp] of the rat Probasin (PB) gene 
designated ARR2PB was linked to the chloramphenicol acetyl transferase (CAT) reporter 
gene (120) and subcloned into the pAdBN plasmid (AdenoQuest Quantum 
Biotechnology, Montreal, Canada) to create pPB-CAT/Ad.  After HPE cells were infected 
with this plasmid, endogenous AR activity was determined following androgen and anti-
androgen treatment. 
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We determined that treatment with the anti-androgen flutamide increased CAT 
reporter gene activity in 2/10 (20%) of tumor and 12/30 (40%) of non-tumor HPE cell 
cultures derived from radical prostatectomy specimens. This agonistic activity occurred in 
the absence of any apparent AR mutations. Interestingly, flutamide treatment appeared to 
increase DJ-1 levels through protein stabilization in a similar manner to that for AR (130). 
DJ-1 functions as an indirect positive modulator of AR activity by allowing AR to 
become transcriptionally active (98). The stabilization of AR and DJ-1 may provide HPE 
cells with a transcriptional advantage that permits them to progress further along the 
pathway of prostate carcinogenesis during ADT.  
 
Results 
 
HPE Cells are Morphologically and Phenotypically Epithelial 
 Histologically, benign human prostatic glands are composed of a layer of 
differentiated secretory luminal cells and a small subpopulation of neuroendocrine cells 
surrounded by a layer of basal epithelial cells (3, 4). Human biopsy fragments from 30 
non-tumor and 10 PCa (Gleason Score 3+3) prostatectomy specimens were placed into 
cell culture under conditions favoring epithelial cell growth as described above. HPE cells 
were passaged for further analysis while the remaining tissue fragments were harvested 
after two weeks for immunohistochemical analysis. A representative immunohistological 
analysis of benign prostate glands in radical prostatectomy specimens before and after 
culture is shown in Figure 1. Before culture, hematoxylin and eosin (H&E) analysis 
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clearly indicated that the basal cell layer was circumferentially intact, surrounding a 
stratified or pseudostratified layer of secretory luminal epithelial cells (Figure 11A). This 
histology was confirmed by double immunofluorescence staining with p63 (a basal 
epithelial cell marker) and cytokeratins 8 and 18 (luminal epithelial cell markers, Figure 
11 B). Both luminal and stromal cells expressed AR, with luminal cells also expressing 
PSA (Figure 11C). In contrast, basal cell hyperplasia was evident after 2 weeks in culture 
(Figure 11D) and this was again confirmed by double immunofluorescence staining with 
p63, CK8 and CK18 (Figure 11E). AR expression was observed in both stromal and 
epithelial cells and often appeared more strongly expressed in hyperplastic basal epithelial 
compared to luminal epithelial cells. Low PSA expression was evident in luminal 
epithelial cells (Figure 11 F).  
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Figure 11: Immunohistochemical analysis of benign prostate glands in radical 
prostatectomy specimens before and after 2 weeks in culture. A to C represent 
the tissue fragments before culture and D to F represent the tissue fragments after 
culture. (A) and (D). Hematoxylin and Eosin stain; basal epithelial cell layer 
(●─●); luminal epithelial cell layer (↔). (B) and (E). Basal epithelial cell marker 
p63 (green); Luminal epithelial cell markers CK8 or CK18 (red). (C) and (F). 
Tissue sections were stained using rabbit polyclonal antibody against human AR 
or goat polyclonal antibody against human PSA. AR (red); PSA (green). 
 
 
Cultured HPE cells were double-stained with immunofluorescence antibodies to 
CK8/CK18 and p63 to determine which cell type was predominant in the bioassay. 
Initially, 100% of the cells were p63 positive, indicating that they were basal epithelial 
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cells (data not shown). With passage number, the number of CK8/CK18 positive cells 
increased and the number of p63 positive cells decreased, suggesting that they had 
undergone differentiation.  Recently, Dalrymple et al reported that the level of calcium in 
tissue culture media affects the population of cells that grow out of cultured tissue 
fragments (131).  They report that high calcium containing medium selects against p63 
positive basal cells allowing luminal epithelial cells to predominate.  We commonly see 
basal cell proliferation in tissue fragments and as the first cells to grow out of the tissue in 
vitro, however determining whether the loss of p63 positive cells with passage number 
was due to differentiation or selection was beyond the scope of this project.   
 
The TIGR assays were performed at passage 3 (unless otherwise stated) since this 
number of passages was required to generate sufficient cells for the TIGR assay. Six 
separate areas per slide were analyzed and the number of CK8/CK18- and p63-expressing 
cells tabulated (Figure 12A-C). Surprisingly, nearly 100% of HPE cells expressed 
CK8/CK18 and 56% of HPE cells co-expressed p63, suggesting that by passage 3, basal 
epithelial cells had differentiated into cells with more luminal epithelial cell 
characteristics (Figure 12C). Further analysis indicated that all HPE cells expressed AR 
and that this expression was primarily nuclear (Figure 12D) whether DHT or the synthetic 
androgen R1881 were present or absent in the cell culture medium. 
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Figure 12: Immunohistochemical analysis of cultured HPE cells. HPE Cells 
were allowed to attach to glass slides and were stained using rabbit polyclonal 
antibody against human p63, mouse monoclonal antibody against human CK8 or 
CK18, rabbit polyclonal antibody against human AR, goat polyclonal antibody 
against human PSA, and monoclonal mouse anti-human adipophilin or CD59. (A) 
Cultured HPE cells derived from prostatectomy fragments in organ culture. (B) 
Expression of p63 (green) or CK8/CK18 (red) at passage 3. (C) The table 
summarizes a representative experiment (HPE 10072, passage 3). Six separate 
areas (i through vi) per section were analyzed for the number of p63 and 
CK8/CK18 positive cells. The DAPI stain represented the number of nuclei and 
therefore, the number of cells per area. Therefore, it was set at 100%. (D) 
Expression of AR (red) and PSA (green) at passage 3. (E) Adipophilin (red) 
expression in primary cultured HPE cells at passage 3. Nuclei were counterstained 
with 4,6-diamidino-2-phenylindole (DAPI) (blue). (F) CD59 expression (red) in 
primary cultured cells at passage 3. Nuclei were counterstained with DAPI (blue). 
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In short-term culture, HPE cells maintained a secretory phenotype. 
Immunofluorescence analysis indicated that within a subpopulation of HPE cells, PSA 
staining appeared typically granular within the cytoplasm (Figure 12D). This pattern of 
expression was similar to that seen in other culture systems (132). Adipophilin, a protein 
component of lipid storage droplets, is associated with cellular differentiation and 
secretion (133, 134). Immunoreactivity to adipophilin was localized in vacuolar, 
intracellular compartments of HPE cells, consistent with lipid droplets (Figure 12E). 
Prostasomes are stored in membrane-bound storage vesicles in prostatic acinar epithelial 
cells and secreted through exocytosis or diacytosis into the glandular lumen (132). HPE 
CD59 immunolocalization determined extracellular, granular and intracellular granular 
staining as seen in prostasomes (Figure 12F). Thus HPE cells in short term culture were 
primarily prostatic epithelial cells which synthesized AR and limited PSA and maintained 
a secretory phenotype as seen by prostasome and adipophilin production. 
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Figure 13: Ultrastructural analyses of HPE cells. HPE cells were analyzed by 
electron microscopy. (A) Large secretory body (**) filled with multiple tightly 
packed concentric membrane lamellae. (B) Smaller secretory bodies (*) 
containing loosely organized membranes. (C) Numerous secretory granules (*) 
released at the apical brush borders between 2 adjacent HPE cells. (D) 
Desmosomes containing attachment plaques with tonofilaments radiating from 
these plagues (<) and brush border vesicle (→). 
 
 
Electron microscopy (EM) analysis of HPE cells further demonstrated their 
epithelial cell characteristics. HPE cells contained numerous larger and smaller secretory 
bodies filled with multiple tightly packed concentric membrane sheets or lamellae (Figure 
13A). Smaller secretory bodies contained loosely organized membranes, suggesting that 
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these represented an early stage in lamellar body formation (Figure 13B). Of particular 
interest was that HPE cells did not lose their brush borders which are essential for the 
processes of exo- and endocytosis. Secretions appeared to be released at the apical brush 
borders as seen by the numerous secretory granules between two adjacent cells (Figure 
13C). Brush border vesicles were also observed (Figure 13D). Neighboring epithelial 
cells are characteristically connected through desmosomes which form focal points of 
cell-cell contact to provide resilience and tensile strength to the epithelial monolayer. 
Desmosomes, containing characteristic attachment plaques with tonofilaments radiating 
from these plagues, formed between adjacent HPE cells (Figure 13D). 
 
HPE Cells Express Endogenous AR 
To analyze the responsiveness of HPE cells to androgen and anti-androgen 
treatment, it was essential that HPE cells express AR. Immunohistochemical analysis 
indicated that HPE cells expressed AR and this was confirmed by Western blot analysis 
(Figure 14A), RT-PCR (Figure 14B), and real-time (RT)-PCR (Figure 14C). Since AR 
protein levels in LNCaP cells were greater compared to those in HPE cells, only 50 ng 
LNCaP protein was run as a positive control. DU-145 cells provided a negative AR 
control. Two µg total RNA for HPE and LNCaP cells were analyzed by real-time RT-
PCR analysis. As predicted, AR levels were greatest in LNCaP cells at 1.5x10-20 µM 
(Figure 14C). In comparison, AR mRNA levels in HPE cell cultures (from 7 different 
representative individuals) ranged from 8.3x10-22 µM to 1.44x10-22 µM.  All HPE cells 
cultured to date have expressed AR, although HPE AR levels were 18 to 104-fold lower 
than those measured in LNCaP cells. Variability of AR expression is a common 
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occurrence in cultured primary HPE cells as well as commercially available, 
immortalized, prostate cancer cell lines (131, 132, 135). Importantly however, most 
prostate adenocarcinomas express AR both in the androgen-responsive and the androgen-
independent stages of the disease; thus, the study of AR in all stages of prostate cancer 
progression is important (48, 62, 64-66, 88). Since all HPE cell cultures express 
endogenous AR, they can be utilized in TIGR assays to characterize the responsiveness of 
primary HPE cells cultured from prostatectomy specimens to androgen and anti-androgen 
treatment.  
 
PSA expression is variable in primary cultured prostate epithelial cells (132). This 
was confirmed in our HPE cell cultures where PSA expression was observed in one of 
seven representative HPE cell cultures derived from tumor specimens (Figure 14B). The 
status of AR affects PSA expression, so it is expected for AR negative cells to lose PSA. 
The reason for PSA and AR expression variability remains largely unclear, although 
culture conditions likely play a role. In order to efficiently grow HPE cells out of tissue 
fragments, androgens must be omitted from the media. Inclusion of androgens prevents 
cell outgrowth from the tissue fragment greatly limiting cell number. Another important 
consideration that partially explains AR variability in the 1980’s literature to that of 
today, is improved sensitivity of techniques used.  Initially, detection of AR protein was 
difficult due to lack of antibodies.  Further, detection of extremely low mRNA species 
was not possible before the advent of RT-PCR. Another aspect of cell culture which 
likely affects expression of differentiation markers is the change in morphology, from a 
tall columnar phenotype adapted to secrete markers into a lumen to a squamous 
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phenotype adapted to cover a tissue culture plate which a cell likely perceives as a wound 
(136). These points highlight the importance of culture conditions and specific starting 
material for establishing primary cell cultures or maintaining existing lines.  
 
Figure 14: Primary HPE cells express AR. HPE primary cultures from 7 
representative patients were analyzed for AR expression. (A) Western blot 
analyses for AR. DU-145 prostate cancer cells served as a negative control. Thirty 
micrograms of HPE or DU145 protein was loaded per lane. Please note that due to 
the greater AR concentration in LNCaP compared to HPE cells, only 50 ng/lane 
LNCaP protein was loaded as a positive control for the purpose of identifying the 
band corresponding to AR. (B) RT-PCR for AR and PSA for the same HPE 
samples as in 4A. DU-145 cells served as negative controls for AR and PSA 
expression. Two µg total RNA were analyzed in each RT-PCR reaction. (C) Real-
time RT-PCR analyses of AR levels in HPE cells. LNCaP served as a positive 
control. 
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Figure 15: Androgen and anti-androgen activity in LNCaP cells. LNCaP cells 
were infected with 108 pfu ARR2PB-CAT/AdBN viral particles. (A) Cells were 
treated with increasing concentrations of R1881 (10-12 to 10-6M) to determine the 
effect of androgen treatment on CAT gene expression. Error bars +/- SD. To 
generate p values, pPB-CAT/Ad and R1881 treatments were compared to pPB-
CAT/Ad alone. ×, p>0.05; ××, p<0.05; ×××, p<0.001. (B) LNCaP cells were 
treated with10-8 M DHT and increasing concentrations of the anti-androgen 
flutamide (10-8 to 10-5M) To generate p values, pPB-CAT/Ad, R1881, and 
flutamide treated samples were compared to pPB-CAT/Ad and R1881 treated 
sample. ×, p>0.05; ××, p<0.05; ×××, p<0.001.  
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AR-regulated Transcription is Activated by flutamide in a Subgroup of HPE cells 
 ADT is still one of the most common strategies for treating prostate cancer. The 
goal of the TIGR assay was to characterize the response of endogenous AR to androgen 
and anti-androgen treatment to determine whether anti-androgen could stimulate AR-
regulated transcription. To achieve this, primary HPE cells were infected with adenoviral 
particles containing the CAT reporter gene linked to the prostate-specific probasin 
promoter (pPB-CAT/Ad) (120). Initially, all adenoviral particles were titrated and 
characterized in the androgen-dependent LNCaP human prostate cancer cell line. No 
difference in basal CAT activity was seen with/without pPB-CAT/Ad, determining that 
these adenoviral particles had no intrinsic biological activity in the absence of androgen 
(Figure 15A). In the presence of pPB-CAT/Ad and increasing concentrations of R1881, 
near maximal CAT activity was observed at 10-8 M R1881 and greater than >99.5% of 
this activity was inhibited at 10-5 M flutamide (Figure 15B). Once the adenoviral particles 
were characterized in LNCaP cells, they were used to compare AR activity in primary 
HPE cells. Due to high levels of endogenous AR in LNCaP cells as compared to HPE 
cells (Figure 14), the absolute value of CAT activity was much lower in HPE cells 
(Figure 16) than that in LNCaP cells (Figure 15). Therefore, the absolute values between 
these cells could not be compared directly; instead they were grouped based upon the 
pattern of activity in response to hormonal treatment. 
 
 The responses of HPE cells to androgen and anti-androgen treatment separated 
into four groups. In the first group, androgen treatment induced CAT gene expression 
11,000-fold and this activity could be blocked nearly 100% by the addition of flutamide, 
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implying that anti-androgen activity was antagonistic on AR-regulated transcription 
(Figure 16A). Thus, these HPE cells were designated as androgen responsive/flutamide 
suppressed (AR/FS).  
 
 In a second group of HPE cells (Figure 16B), basal CAT gene expression 
increased 195-fold in the absence of hormonal treatment. This observation was surprising 
since CAT activity did not increase above basal levels in LNCaP, PC-3 or AR/FS HPE 
cells under similar culture conditions. Flutamide treatment was still antagonistic, resulting 
in the partial suppression (57%) of this basal activity, suggesting that the increase in CAT 
activity was, at least in part, due to transactivation of the AR signaling pathway. 
Furthermore, the addition of 10-8 M R1881 had little effect; however the addition of 
flutamide alone still inhibited 52% of CAT activity in the presence of androgen. These 
HPE cells were therefore designated as androgen independent/flutamide suppressed 
(AI/FS). 
 
 In group 3 (Figure 16C), elevated CAT activity (42-fold) was again observed in 
the absence of hormonal treatment and this activity was not increased by the addition of 
androgen, suggesting that these HPE cells produced factors which could stimulate AR-
regulated transcription. Furthermore, flutamide treatment was agonistic, increasing CAT 
activity a further 2.2-fold and in combination with androgen, an additional 4-fold, 
indicating that the effects of androgen and anti-androgen treatment on AR-regulated CAT 
gene expression were additive. Since androgen treatment alone had little effect and 
flutamide activated AR-regulated transcription (through an androgen responsive 
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promoter) in the absence and presence of androgen, these HPE cells were designated as 
androgen independent/flutamide activated (AI/FA). 
 
 In Group 4 (Figure 16D), increased levels of CAT activity (12-fold) were 
determined in the absence of androgen and the addition of androgen or flutamide did no                                                                                                                                                                                
t alter this activity. Thus, these HPE cells were categorized as non-responsive (NR) to 
androgen or anti-androgen treatment. Table 3 summarizes the response of HPE cells to 
androgen or anti-androgen treatment.  
 
 Table 3: Summary of the Agonist and Antagonist Activities of Flutamide on 
 Androgen Receptor-Induced Signaling in the TIGR assay. A total of 40 
 primary HPE cell cultures were analyzed in this study. Ten specimens were PCa 
 tissue (Gleason score 3+3) and 30 specimens were non-tumor tissue obtained from 
 areas adjacent to the PCa lesion. This table summarizes the data obtained from the 
 TIGR assays.  
HPE cell 
response 
Description of response to androgen and  
antiandrogen treatment  
Gleason 
score 3+3 
non-
tumor 
tissue 
 
AR/FS 
- Androgen Responsive/Flutamide Suppressed  
  - androgen treatment induces CAT activity 
  - flutamide inhibits androgen-induced CAT activity 
0/10 4/30 
 
AI/FS 
- Androgen Independent/Flutamide Suppressed 
  - androgen treatment does not induce CAT activity 
  - flutamide inhibits AR-regulated CAT activity 
7/10 10/30 
 
AI/FA 
 
- Androgen Independent/Flutamide Activated 
  - androgen treatment does not induce CAT activity 
  - flutamide is agonistic, promoting AR-regulated 
  CAT activity 
2/10 12/30 
 
NR 
- Non-Responsive 
  - androgen or flutamide treatment do not induce or 
  inhibit CAT reporter gene expression 
1/10 4/30 
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HPE cells from passage 2 were compared with those from passage 4 (derived from 
the same specimen) to determine whether passage number influenced response to 
flutamide treatment. As seen in Figure 17, the agonistic activity of flutamide induced 
CAT gene expression at both passage 2 (3.5-fold) and passage 4 (2-fold), indicating that 
the response to anti-androgen treatment was not dependent on passage number. 
Furthermore, HPE cells cultured from the transitional zone (TZ) responded in a similar 
manner to flutamide (2.6-fold increase) as those from the peripheral zone (PZ). The same 
response, whether flutamide activation or flutamide suppression, was observed in 60% of 
TIGR assays where PZ and TZ HPE cells were derived from the same prostate, 
suggesting that the antagonist or agonist activity of flutamide on AR-regulated 
transcription appeared to be an inherent response of HPE cells within that prostate. 
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Figure 16: Androgen and anti-androgen activity in HPE cells. 1 x 105 HPE 
cells/well were plated in quadruplicate in 24 well plates and the cells were 
infected with 108 pfu pPB-CAT/Ad viral particles. The cells were treated with 
ethanol, 10-8M R1881, or with 10-5M flutamide as indicated and CAT activity was 
determined as described previously [23]. Error bars, +/- SD. The asterisk indicates 
p values of pPB-CAT/Ad and ethanol compared to ethanol alone. *, p<0.007; **, 
p<0.001; *** p<0.0001. The ^ symbol indicates p values of pPB-CAT/Ad and 
R1881 or flutamide treatment compared with pPB-CAT/Ad and ethanol treatment. 
^, p<0.016. 
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Figure 17: Comparison of HPE cells cultured from different passage numbers 
or prostate regions to androgen and anti-androgen treatment. HPE cells from 
passage 2 (P2) were compared with those from passage 4 (P4) (derived from the 
same prostatectomy specimen) or from peripheral (PZ) or transitional (TZ) zones 
of the prostate to determine whether passage number or location influenced 
response to flutamide treatment. CAT assays were performed as describes 
elsewhere [23]. (A) HPE cells from P2 were plated in quadruplicate at 1 x105 HPE 
cells/well, infected with 108 pfu pPB-CAT/Ad viral particles and treated with 10-
8M R1881 or with 10-5M flutamide as indicated. (B) HPE cells from P4. (C) HPE 
cells from the prostate TZ. Error bars, +/- SD values. The asterisk indicates p 
values of pPB-CAT/Ad and ethanol compared to ethanol alone. *, p<0.0001. The 
^ symbol indicates p values of pPB-CAT/Ad and flutamide treatment compared 
with pPB-CAT/Ad and ethanol. ^, p< 0.007; ^^. p<0.0006; ^^^, p<0.0001. The + 
symbol indicates p values of pPB-CAT/Ad, R1881 and flutamide treatment 
compared with pPB-CAT/Ad and ethanol. +, p<0.09; ++, p<0.02; +++, p<0.003. 
The ○ symbol indicates p values of pPB-CAT/Ad, R1881 and flutamide treatment 
compared with pPB-CAT/Ad and R1881. ○, p<0.019; ○○, p<0.001; ○○○, 
p<0.0002. 
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Mutational analysis of AR in HPE cells where AR-regulated signaling was activated 
by flutamide 
 
 AR mutations may allow transactivation of AR signaling through other steroid 
hormones and ligands such as corticoids and flutamide (72, 137). Thus, AR in AI/FA 
HPE cells was analyzed for somatic mutations. Genomic DNA was extracted from 
cultured HPE cells and PCR amplification was performed on six targeted areas in which 
most of the prostate cancer somatic mutations co-localized. These areas include 2 in the 
AR-NTD [amino acids (aa) 54-92; 253-282;] and 4 in the AR-HBD [aa 654-689; 688-
721; 723-738; 867-917] (67). No point mutations, insertions or deletions in these 6 areas 
were identified. These observations do not exclude the possibility that mutations could 
have been present outside of these common regions.  
 
Identification of DJ-1 in HPE cells treated with flutamide 
 Difference gel electrophoresis was used to flag DJ-1 as a protein that underwent a 
change in expression level upon hormonal treatment. Briefly, HPE cells were treated with 
ethanol, 10-8 M R1881, or 10-5 M flutamide, harvested and lysed as described in materials 
and methods. One hundred µg of each whole cell lysate was labeled with Cy2, Cy3, or 
Cy5 respectively, recombined and subjected to 2D gel electrophoresis (Figure 18A). The 
resulting 2D gel was visualized under the appropriate wavelengths and protein spots that 
increased with flutamide treatment relative to the ethanol control (Figure 18B) were 
excised, treated with trypsin, and analyzed by mass spectrometry (Figure 18C). DJ-1, a 
positive regulator of AR activation (98), was identified as increasing 1.44-fold (44%) with 
flutamide treatment. The ion signals at m/z = 1158.62, 1286.70, 1707.79, 1920.99, and 
2584.36 were used to identify DJ-1 using a peptide mass mapping strategy (Materials and 
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Methods), yielding statistically-significant search scores, 37% protein coverage, and a 
database-predicted MW and isoelectric point (20,100 kDa and 6.3 pI) that were consistent 
with the gel region. This preliminary finding was validated in the following experiments. 
 
 
 
 
Figure 18: Identification of DJ-1, a flutamide-regulated protein, in HPE cells. 
(A) Total protein stain image of the 2D-gel used for the difference gel 
electrophoresis analysis, wherein separately-labeled total protein extracts from 
HPE cells treated with ethanol, R1881, or flutamide were co-resolved. The arrow 
indicates the protein spot-of-interest that was determined to be DJ-1. (B) The 
boxed region from panel A is enlarged and Cy2 and Cy5 are individually imaged 
to show the increase in protein expression between the ethanol and flutamide 
treated samples. Below each gel is a graphical representation of increase in protein 
levels. (C) Protein profile of the tryptic peptides which identified the protein as 
DJ-1.  
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Flutamide and androgen regulate DJ-1 and AR expression 
 Due to limited tissue fragments and the short lifespan of HPE cells in culture, it 
was important to identify an immortalized cell line expressing DJ-1 to confirm the 
primary culture data. Therefore LNCaP, PC-3, DU-145, and NIH-3T3 cells were analyzed 
for DJ-1 expression (data not shown). Although all cell lines tested expressed DJ-1, 
LNCaP cells were selected since they also expressed endogenous AR which could be 
transactivated by hydroxyflutamide (OHF), albeit through a T877A substitution mutation. 
LNCaP cells were deprived of androgens and treated with different activators of 
transcriptional regulation including 10-8M DHT, 10-8M R1881, 10-5 hydroxyflutamide 
(OHF), 10-5 M Forskolin, or 10-6M TPA, for 48 hours. The vehicle (ethanol) served as a 
control. Forskolin and TPA were included to determine whether DJ-1 expression was 
modulated by other transcriptional regulators such as adenylate cyclase or AP1 
respectively. Western blot analysis demonstrated that DJ-1 protein levels increased up to 
6-fold with R1881 and OHF treatment (Figure 19A). DJ-1 expression also increased in 
LNCaP cells that were deprived of androgens for 24 hours (CSS) and then returned to 
media containing 10% FBS (CSS+FBS). Forskolin and TPA treatment had limited effect, 
increasing DJ-1 expression only 2-fold (Figure 19B). Thus, DJ-1 expression appeared to 
be primarily modulated by R1881 or OHF treatment. AR expression also increased or 
decreased in parallel with DJ-1 in all treatment groups. 
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Figure 19: Androgens and anti-androgens increase protein levels of DJ-1 and 
AR. (A) LNCaP cells were grown to 70% confluency and changed to media 
containing 10% charcoal stripped fetal calf serum (CSS). After 24 hours of 
androgen depletion, cells were treated with the indicated agents for 48 hours. CSS 
alone served as a negative control (lane 7), while CSS for 24 hours followed by 24 
hours with 10% FBS served as a positive control (lane 8). (B) AR and DJ-1 
protein levels are represented as a histogram after normalization to GAPDH 
loading control. 
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DJ-1 protein is stabilized in response to androgen and anti-androgen treatment 
 LNCaP cells were treated with ethanol, 10-8 M DHT, or 10-5 M OHF for 24 hours, 
total RNA was extracted and Northern blot analysis was performed to determine whether 
the increase in DJ-1 protein levels was due to increased DJ-1 gene transcription. A 
riboprobe to full-length human DJ-1 was labeled with 32P. Unlabeled antisense RNA 
served as a negative control and DJ-1 plasmid as a positive control. No change in DJ-1 
mRNA levels was observed at all time points tested (Figure 20A).  
 
 Since androgen and anti-androgen treatment did not appear to regulate DJ-1 gene 
expression, LNCaP cells were treated with the translation inhibitor cyclohexamide (CHX) 
to test whether hormone treatment stabilized DJ-1 protein. After 30 minutes of 
pretreatment with ethanol, DHT, or OHF, CHX was added and cells were harvested at 24, 
48, and 72 hours and processed for Western blot analysis (Figure 20B and 20C). DJ-1 
protein levels remained unchanged even up to 72 hours after OHF treatment whereas DJ-
1 protein was reduced by 60% with ethanol treatment. DHT stabilized DJ-1 slightly as 
compared to ethanol control which correlates with the greater increase of DJ-1 following 
OHF treatment (Figure 19A). These results imply that the increase in DJ-1 protein levels 
is due to increased protein stability during androgen and anti-androgen treatment. 
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Figure 20: Increased DJ-1 Protein Expression after OH-Flutamide Treatment 
Results from Protein Stabilization. (A) Northern blot analysis of DJ-1 using 
total RNA from LNCaP cells. Cells were treated either with ethanol, DHT, or OH-
Flutamide (OHF) for the amount of time indicated above each lane. DJ-1 plasmid 
was used as a positive control (+). Unlabeled antisense RNA was used as a 
negative control (-). (B) Cyclohexamide Stabilization Assay for DJ-1. LNCaP 
cells were again deprived of androgens and then were pretreated either with 
ethanol, DHT, or OHF for 30 minutes prior to treatment with cyclohexamide 
(CHX). Cells cultured in CSS media and were not treated with CHX serve as 
controls at 0 and 72 hours. (C) Densitometry shows that treatment with OHF 
stabilizes DJ-1 protein for 72 hours after addition of CHX, whereas approximately 
50 % degrades with DHT treatment, and 60% by 72 hours in the EtOH treated 
sample. Values for DJ-1 were normalized to the GAPDH loading control. 
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Discussion 
Anti-androgens such as flutamide and bicalutamide have been used in 
combination with ADT for PCa. The HPE TIGR assay was developed to study the effects 
of androgen and anti-androgen treatment in primary HPE cells since these cells most 
closely represent those from the patient. Unlike other PCa cell lines which were derived 
from metastatic lesions or from virally transformed cell cultures, HPE cells were cultured 
from biopsy material only up to passage 4 to capture the early responses of AR-regulated 
transcription to hormone therapy. These cells were typically epithelial and expressed 
prostatic secretory proteins. A further advantage of HPE cell cultures was that the assay 
measured endogenous AR responses to androgen and anti-androgen treatment. 
Endogenous AR activity was significantly lower than that observed in studies where 
exogenous AR was transfected into cells to promote high levels of reporter gene activity 
(138). The lower levels of CAT activity most likely reflect the physiological levels of 
AR-regulated signaling in the prostatic epithelium.  
 
The most surprising observation was that flutamide promoted AR-regulated 
transcription in HPE cells derived from 2/10 (20%) tumor and 12/30 (40%) nontumorous 
biopsy specimens. These observations suggested that transcriptional activation by 
flutamide occurred in cells derived from histologically normal prostate tissue. Flutamide 
promotes androgen-independent transcriptional activation and proliferation through the 
well-characterized AR T877A substitution mutation in LNCaP cells (72, 137). This 
mutation was detected in 5 of 16 metastatic lesions obtained from patients who received 
combined androgen blockade with flutamide (69). We analyzed this region in the AR 
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from AI/FA HPE cells. No mutations, including the T877A mutation, were identified, 
demonstrating that the agonist activity of flutamide occurred through a wild-type AR 
(130). In a similar study, hydroxyflutamide treatment increased reporter gene activity in 
DU-145 transfected with wild-type AR. Our analysis does not eliminate the possibility 
that as yet unidentified mutations may have occurred outside the common areas analyzed. 
 
 Difference gel electrophoresis analysis of HPE cells identified the oncogene DJ-1 
as a protein whose expression was increased by anti-androgen treatment. PIASxα [protein 
inhibitor of activated STAT (signal transducer and activator of transcription)] interacts 
with the DNA-binding domain/zinc finger region of AR and suppress AR-activated 
transcription (139). DJ-1 was identified as a PIASxα binding partner, interacting directly 
with the AR-binding region of PIASxα to remove it from AR and restore AR 
transcriptional activity (98).  
 
In our study, DJ-1 protein levels increased in parallel with AR in response to 
flutamide as well as to R1881. In addition, DJ-1 protein levels were stabilized by 
flutamide similar to that observed for AR (130). Thus, it is possible that stabilization of 
AR and DJ-1 allowed flutamide to gain agonist activity. This mechanism may account, in 
part, for the anti-androgen withdrawal syndrome. 
 
 In addition to PIASxα, DJ-1 interacts with the death protein DAXX, sequestering 
it in the nucleus and inhibiting apoptosis signal-regulating kinase 1 activity to promote 
cell survival (94). DJ-1 binding protein (DJBP) binds to the DNA binding domain to AR 
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and negatively regulates AR by recruiting histone deacetylase complex, including 
HDAC1 and mSin3 (118). DJ-1 restores AR activity by interacting with DJBP (118). 
Thus, DJ-1 appears to play a major role in AR function. 
 
 The ARR2PB promoter contains two androgen responsive regions, each containing 
two androgen receptor binding sites ARBS1 and ARBS2 (120). This reporter is 
exquisitely sensitive to androgen and anti-androgen treatment. Low/no CAT activity was 
observed in the untreated control groups in AR/FS HPE, LNCaP, and PC-3 cells. This 
was in contrast to HPE cells in the AI/FS, AI/FA, and NR groups which all demonstrated 
high basal levels of CAT activity in the absence of hormonal treatment. Flutamide could 
still suppress 57% of this activity, implying that this activity was, in part, promoted 
through the AR signaling pathway. Since this blockade was not 100%, it is possible that 
HPE cells produce factors in addition to DJ-1 that promote AR-regulated promoter 
activity in the absence of androgen. 
 
 Stabilization of AR and positive regulators such as DJ-1 may partially explain the 
progression from anti-androgens functioning as AR antagonists to agonists. This 
stabilization may provide the double-edged sword for cancer progression. Not only is AR 
protein itself stabilized, similar to the hypersensitivity hypothesis whereby increased 
levels of AR allow the cell to respond to extremely low androgen levels (48), but also DJ-
1 and other AR co-regulators are stabilized which promote transcriptional activation of 
AR. Taken together these changes could provide the transcriptional advantage that allows 
hormone responsive cancers to escape ADT. 
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 Our study using primary cultured HPE cells suggests that anti-androgens can 
become agonists by stabilizing DJ-1 and increasing DJ-1 and AR protein levels. The 
agonistic activity of flutamide was already observed in histologically normal HPE cells, 
suggesting that these cells had a transcriptional advantage for survival and that these 
changes may occur before the disease is clinically diagnosed. Thus, the HPE TIGR cell 
assay provides a mechanism for studying the early molecular changes which allow anti-
androgens to acquire agonistic properties and highlights the importance of utilizing cells 
derived from radical prostatectomy specimens in determining these mechanisms. 
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CHAPTER IV 
 
DJ-1 BINDS ANDROGEN RECEPTOR DIRECTLY AND MEDIATES ITS 
ACTIVITY IN HORMONALLY TREATED PROSTATE CANCER CELLS 
 
 
 
Introduction 
Multiple molecular events are involved in prostate cancer (PCa) initiation, 
growth, invasion, and metastasis.  Despite the diverse etiology, there is at least one 
universal similarity to the disease – the requirement of androgens and AR for tumor 
progression (49, 140-145). Androgen deprivation therapy (ADT, also known as neo-
adjuvant hormone therapy), is initially effective to treat prostate cancer and remains the 
most common treatment regimen for advanced disease. Although androgen deprivation 
therapy initially causes tumor regression, the eventual evolution of PCa from an 
androgen-dependent to an androgen-independent phenotype allows continuation of tumor 
progression (reviewed in (146)).  There are many hypotheses for the development of 
androgen-independent prostate cancer. Some of these involve increased cellular 
proliferation/decreased apoptosis and, in some patients, increased serum prostate-specific 
antigen (PSA) corresponding with promiscuous or increased AR activity (48, 116). 
 
We hypothesized that identification of proteins that increase following androgen 
deprivation therapy would modulate molecular changes that promote and/or maintain 
AIPC. To this end, we performed proteomic analysis of primary HPE cells after treatment 
with the anti-androgen flutamide (128). We identified DJ-1 as one protein that increased 
following flutamide treatment. Western blot analysis confirmed this result, demonstrating 
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that DJ-1 and AR protein levels increased following treatment with dihydrotestosterone 
(DHT), the synthetic androgen R1881, or the anti-androgen hydroxy-flutamide (OH-
flutamide) in LNCaP cells. Blocking protein synthesis with cycloheximide revealed the 
increase in DJ-1 was due to increased protein stability (128). This indicates DJ-1 and AR 
expression are regulated by both androgens and anti-androgen therapy and could play a 
role in AIPC.  
 
 In order to elucidate the DJ-1 pathway in PCa, we sought to identify DJ-1 
binding proteins in prostate epithelial cells. To address this, primary HPE cells were 
derived from a punch biopsy of human prostate and the androgen-responsiveness of these 
cells was determined using the TIGR assay as described (128). Briefly, this assay utilizes 
an androgen-responsive reporter to determine whether primary HPE cells are androgen 
responsive, androgen independent, or flutamide activated. Since we previously 
demonstrated that DJ-1 increases after flutamide treatment, we used flutamide activated 
HPE cells to generate a novel cDNA library. This library was screened using DJ-1 and 
identified AR as a DJ-1 binding partner. Previously, DJ-1 was thought to control AR 
activity through an indirect mechanism, although these studies were performed after 
transient transfection of AR and DJ-1 in non-prostate cell lines (98, 118). This is the first 
evidence that endogenous DJ-1 directly binds AR, and that the sub-cellular localization 
and protein-protein interaction is hormonally regulated.  Further, we analyzed two 
prostate cancer tissue arrays providing the first large-scale expression analysis for DJ-1 in 
PCa. The first of the two arrays is arranged by Gleason pattern, and the second is 
arranged by length of time of ADT.  DJ-1 immunohistochemical staining on these arrays 
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demonstrates for the first time that DJ-1 is expressed in benign as well as high Gleason 
pattern regions.  Interestingly, DJ-1 expression increased significantly in patients 
receiving greater than 6 months of ADT, indicating that DJ-1 may contribute to the 
development of AIPC. Taken together, these data provide a new mechanism for 
regulation of AR in androgen independent prostate epithelial cells.  
 
 
Results 
 
 
DJ-1 Binds the Androgen Receptor 
 In order to identify DJ-1 binding partners in PCa we generated a cDNA library 
from primary human prostate epithelial cells where flutamide treatment activated AR 
signaling in an androgen-independent manner. This unique library was generated because 
our previous studies indicated that DJ-1 expression increased in HPE and LNCaP cells 
following anti-androgen treatment.  Screening the flutamide-activated library allows 
identification of DJ-1 binding partners that may contribute to the development or 
maintenance of AIPC. Therefore, full length DJ-1 cDNA was used to screen the library 
and identified a region of AR (Figure 21B). The AR fragment contains a region of the N-
terminal activation domain, the entire DNA Binding Domain, and a portion of the Ligand 
Binding Domain (Figure 21A). 
 
The DJ-1:AR interaction was confirmed using AR immunoprecipitation (IP) in 
the LAPC4 cell line. These androgen-dependent cells were derived from a lymph node 
metastasis and retain wild-type AR and PSA expression, unlike most PCa cell lines that 
 83 
have lost AR expression or have AR mutations (147).  IP of endogenous AR pulls down 
DJ-1 (Figure 21C).  The reciprocal IP was performed in LAPC4 cells expressing a N-
terminal HA-tagged DJ-1.  IP using anti-HA antibody co-immunoprecipitated HA tagged 
DJ-1, endogenous DJ-1, and AR. DJ-1 exists as an obligatory dimer (100). Therefore, we 
postulate that HA-DJ-1 binds endogenous DJ-1, explaining the precipitation of both 
tagged and un-tagged DJ-1 (Figure 21D).  
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Figure 21: AR Binds DJ-1 in the Yeast Two-Hybrid System and LAPC4 Cell 
Line 
A) The fragment of AR identified spans the C-terminal region of the Activation 
Domain, the DNA Binding Domain, and a portion of the Ligand Binding Domain.  
B) High                                                                                                                   
stringency selection demonstrates that neither the bait (DJ-1) nor prey (AR) 
plasmid are capable of activating reporter genes individually, but the combination 
produces an interaction and activation of the reporters. 
C) Immunoprecipitation (IP) of AR in LAPC4 cells pulls down DJ-1 confirming 
the interaction.  D) Reciprocal IP was performed using LAPC4 cells that express 
HA-tagged DJ-1. Input lane contains total protein, mock IP was performed with 
anti-IgG antibody to demonstrate specificity. 
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Hormonal Treatment Increases The Interaction Between DJ-1 and AR 
 We performed IPs following hormonal treatment in LAPC4 and LNCaP cells to 
determine if these treatments regulated the DJ-1:AR interaction.  LAPC4 and LNCaP 
cells were serum starved overnight and then treated with ethanol, 10-8M DHT (LNCaP), 
10-9M DHT (LAPC4), 10-5M OH-flutamide (LNCaP), 10-6M OH-flutamide (LAPC4), 10-
5M bicalutamide (LNCaP), or 10-6M bicalutamide (LAPC4) for 24 hours. In both LAPC4 
and LNCaP cells, anti-androgen treatment with either OH-flutamide or bicalutamide 
increased the amount of DJ-1 bound to AR (Figure 22).  DHT treatment appeared to 
increase the DJ-1:AR interaction in LNCaP cells more so than in LAPC4 cells (Figure 
22).  
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Figure 22: Hormonal Treatment Increases DJ-1:AR Interaction in LAPC4 
and LNCaP Cell Lines 
AR immunoprecipitation following treatment of LAPC4 and LNCaP cell lines 
with ethanol, DHT, OH-flutamide, and bicalutamide.  Input lanes contain 5 
micrograms of total protein lysate from DHT treated sample.  Mock IP was 
performed with anti-IgG.   
 
 
 
Androgen and Anti-Androgens Increase DJ-1 Nuclear Localization 
In order to determine localization of DJ-1 in the prostate cancer cell lines LAPC4 
and LNCaP, nuclear and cytoplasmic extracts were prepared. Cells were treated as 
described above.  Twenty-four hours after treatment, cells were harvested and 
cytoplasmic and nuclear extracts were prepared using the NEPER kit (Pierce).  Western 
Blot analysis of the resultant extracts revealed that DJ-1 is predominantly cytoplasmic, 
but both androgen (DHT) and anti-androgen (OH-flutamide and bicalutamide) treatment 
 87 
increases DJ-1 expression in the nuclear fraction (Figure 23A).  As expected, AR 
expression was very low in the absence of androgens, but when treated with DHT, AR 
expression is increased and predominantly nuclear (Figure 23A).  Histone H1 and Rho A 
were used as nuclear and cytoplasmic controls, respectively, and to show equal loading 
between lanes (Figure 23A) (148).  The same experiment was performed in LNCaP cells, 
where an increase in DJ-1 after hormonal treatment was previously documented (128). 
The LNCaP cell line also showed increased nuclear DJ-1 after hormonal treatment, with a 
greater increase in nuclear DJ-1 with DHT than in the LAPC4 cell line (Figure 23B). AR 
is predominantly nuclear in all treatment groups, consistent with previous reports (65, 
149, 150).  Histone H1 and Rho A demonstrate clear separation between the subcellular 
compartments (Figure 23B). 
 
 Immunofluorescence and confocal microscopy were used to confirm the presence 
of DJ-1 in both nuclear and cytoplasmic compartments.  LAPC4 and LNCaP cells were 
plated on chamber slides, allowed to attach overnight, then treated in the same manner as 
cells used for nuclear/cytoplasmic extracts.  Cells were stained for DJ-1, AR, and SC-35 
and visualized with appropriate secondary antibodies.  SC-35 is a nuclear speckle marker, 
and was included to identify sites of active transcription (151).  As with nuclear and 
cytoplasmic extracts, DJ-1 (green) is predominantly cytoplasmic, but is also present in 
the nucleus in both LAPC4 and LNCaP cell lines (Figure 23C). AR (red) localization also 
confirms results from nuclear and cytoplasmic extracts, in that AR expression was low in 
the absence of androgens in LAPC4 cells, but driven to the nucleus upon treatment with 
DHT (Figure 23C).  Further, AR positive nuclei were observed regardless of treatment in 
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LNCaP cells, confirming our observations from Western blot analyses (Figure 23C).  The 
merged images show co-localization between DJ-1 and AR, indicated by yellow in 
merged images (Figure 23C, white arrows) but these areas appear distinct from nuclear 
speckles and active sites transcription (Figure 23C, white *). Low-magnification images 
of individual channels are shown in inset areas (Figure 23C).  
 
Yellow pixels, from the LNCaP images in Figure 3C, were displayed alone and 
indicate DJ-1:AR co-localization increases following hormonal treatment (Figure 23D). 
White dashed lines outline nuclei (Figure 23D). Co-localization of DJ-1 and AR was 
quantified by determining the percentage of co-localized pixels per image (Figure 23D). 
DJ-1:AR co-localization was greatest with DHT treatment followed by OH-flutamide and 
then bicalutamide treatment. Each treatment demonstrated a distinct pattern. DHT and 
bicalutamide treatment resulted in similar co-localization throughout the nucleus, 
whereas DJ-1:AR with OH-flutamide treatment appeared to concentrate just within the 
nuclear perimeter. DJ-1:AR co-localization was not quantified in LAPC4 cells due to low 
AR levels except after DHT treatment. 
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Figure 23: Androgens and Anti-androgens Increase DJ-1 Nuclear 
Localization in LAPC4 and LNCaP Cells   
Nuclear and cytoplasmic extracts were prepared from A) LAPC4 cells and B) 
LNCaP cells indicated treatments. C) Immunofluorescence for DJ-1 (green), AR 
(red), and SC-35 (blue) in LAPC4 and LNCaP cells following treatment. Merged 
high-magnification images show co-localization between DJ-1 and AR (yellow 
spots) indicated by white arrows.  Co-localization between AR and SC-35 
(pink/purple spots) indicated by white asterisk mark active sites of transcription. 
Scale bar equals 5 microns. D) Images and quantification of co-localization 
between DJ-1 and AR.  Yellow pixels indicate co-localization between DJ-1 and 
AR in LNCaP cells.  White dashed lines outline several nuclei. The percent of 
pixels that co-localize between DJ-1 and AR channels was determined in multiple 
optical slices for each treatment in LNCaP cells and is represented as mean +/- 
SEM. Scale bar equals 5 microns. 
 
 
 
DJ-1 Regulates AR Transcriptional Activity 
 We used an androgen-responsive luciferase reporter to determine how modulation 
of DJ-1 expression affected AR activity.  A region of the probasin promoter, termed 
(ARR2PB), containing two androgen responsive regions, was cloned upstream of the 
Firefly luciferase gene resulting in the ARR2PB-luc reporter (128, 129). Over-expression 
of DJ-1 (HA-DJ-1 + luc) increased AR activity approximately 10-fold (p<0.001) 
compared to parental LAPC4 cells transfected with the luciferase reporter and to cells 
transfected with reporter and an empty plasmid control (Figure 24A). Western Blot 
analysis demonstrates that transfection with pCruz-HA-DJ-1 plasmid doubles the 
expression level of DJ-1, but does not change the expression level of AR (Figure 24B).   
 
 Similarly to over-expression, knockdown of DJ-1 expression influences AR 
regulated-transcription.  Pooled siRNAs were co-transfected into LAPC4 cells along with 
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the ARR2PB-luc reporter. Knockdown of DJ-1 expression decreased AR activity 5-10 
fold compared to LAPC4 cells with reporter alone (p<0.01) (Figure 24C). The decrease 
in DJ-1 expression after transfection of siRNAs resulted in approximately 50% decrease 
in DJ-1 protein level compared to GAPDH loading control (Figure 24D). Transfection of 
nonspecific (NS) siRNA served as a control and did not change DJ-1 expression 
compared to nontransfected LAPC4 cells.  Knockdown of DJ-1 did not change AR 
expression, indicating that AR expression is not regulated by DJ-1 (Figure 24D).  
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Figure 24: DJ-1 Regulates AR Transcriptional Activity in LAPC4 Cells 
A) Overexpression of DJ-1 (HA-DJ-1) increases AR transcriptional activity using 
the ARR2PB-luciferase (luc) reporter compared to reporter alone. Each bar 
represents the mean of three samples +/- SEM after normalization to protein 
concentration and expressed as fold change compared to nontransfected control.  
This experiment was repeated 3 times with the same result. B) Western blot of 
LAPC4 cells transfected with HA-DJ-1 plasmid compared to parental LAPC4 
cells. AR expression level does not change with overexpression of DJ-1.  GAPDH 
was included as a loading control.  C) Knockdown of DJ-1 expression using 
siRNA decreases AR activity as compared to reporter alone. Nonspecific siRNA 
(NS) indicates that the effect is specific.  Samples are presented in the same 
manner as in panel A. D) Western blot of LAPC4 cells transfected with siRNAs 
shows that DJ-1 siRNA decreases expression by 50%. AR expression does not 
change after knockdown of DJ-1. The percent knockdown of DJ-1 compared to 
NS siRNA was determined by densitometric analysis using ImageJ software. 
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DJ-1 Expression Does Not Increase With Gleason Pattern 
 
Prostate samples from patients who underwent radical prostatectomy between 
1989 to 2003 were obtained from Vancouver General Hospital.  These patients received 
no treatment prior to surgery. The samples were grouped based upon Gleason score and 
arranged on the slide based upon predominant Gleason pattern for each tissue core in the 
following groups: Benign, Gleason 2, Gleason 3, Gleason 4, and Gleason 5. Figure 25A 
indicates the number of patients represented by each group. 
 
DJ-1 immunohistochemical staining was performed on this array and quantitated 
based on intensity.  Four areas per tissue core were evaluated using the following scale:  
“0” indicates no staining of any cells, “1” indicates a faint stain, “2” indicates a moderate 
intensity stain, and “3” indicates intense staining.  DJ-1 was present in all 5 sample 
groups at moderate intensity, but no statistically significant change was observed, 
indicating that DJ-1 does not increase with Gleason pattern (Figure 25B).  Figure 25C 
shows representative areas from each group at low and high magnifications (scale bars 
equal 20 microns).  DJ-1 is predominantly expressed in luminal epithelial cells and is 
both cytoplasmic and nuclear.   
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Figure 25:  DJ-1 Expression Does Not Increase With Gleason Pattern 
A) The number of patients represented per group on the TMA.  B) Quantification 
of DJ-1 staining intensity on the Gleason TMA.  Staining intensity was evaluated 
on a 4 point scale, with “0” indicating no positive cells, and “3” indicating 
intensely positive cells.  DJ-1 is moderately expressed in all groups and does not 
increase with Gleason pattern.  Bars represent mean +/- SEM. C) Representative 
immunohistochemistry images from each of the groups on the array at low and 
high magnification.  DJ-1 is expressed predominantly in the luminal epithelial 
cells and is both cytoplasmic and nuclear. Scale bars equal 20 microns. 
 
 
DJ-1 Expression Increases in Human Prostates with Androgen Deprivation Therapy 
(ADT):  
 
The second tissue array was generated identically to the first.  This array was 
composed of samples from patients who received either no ADT, less than 3 months 
ADT, 3-6 months ADT, or greater than 6 months ADT before undergoing radical 
prostatectomy surgery at Vancouver General Hospital.  The samples were evaluated 
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histologically and arranged based upon duration of treatment. Figure 26A indicates the 
number of patients per group (unshaded boxes). 
 
DJ-1 staining intensity was evaluated in the same manner as on the Gleason tissue 
array. DJ-1 expression increased significantly in the greater than 6 months ADT group as 
compared to the untreated group (p<0.01) (Figure 26B). Figure 26B shows representative 
tissue cores from each treatment group at low and high magnification (scale bars equal 20 
microns).  DJ-1 is expressed in both the cytoplasm and nuclei of luminal epithelial cells. 
The increase in the intensity of DJ-1 staining after prolonged ADT treatment suggests 
that DJ-1 may be involved in the emergence of AIPC as our previous data suggested. 
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Figure 26:  DJ-1 Expression Increases Following Prolonged Androgen 
Deprivation Therapy (ADT) 
A) The number of patients represented per group on the TMA.  B) Quantification 
of DJ-1 staining intensity on the ADT TMA. Samples are grouped by amount of 
time of ADT and DJ-1 staining intensity was evaluated on a 4 point scale, with 
“0” indicating no positive cells, and “3” indicating intensely positive cells.  DJ-1 
expression increases significantly in the greater than 6 months ADT group 
(p<0.01). Bars represent mean +/- SEM.  B) Representative 
immunohistochemistry images from each of the groups on the array. Scale bars 
equal 20 microns. 
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Discussion 
DJ-1 is a diverse signaling protein that appears to have multiple roles that may 
largely depend on cell type and cellular environment (91, 93-95, 97-99). DJ-1 was 
initially thought to activate AR through indirect mechanisms, for example, by interacting 
with the AR binding region of PIASx-alpha (Protein Inhibitor of Activated STAT-alpha) 
and preventing it from binding and inhibiting AR (98). However, it has also been 
reported that DJ-1 represses AR activity in the SK-N-BE(2)C neuroblastoma cell line 
(119). From these conflicting reports, it appears that DJ-1 regulation of AR may be cell 
type dependent.  We demonstrate that DJ-1 directly interacts with AR and that DJ-1 
functions as a positive regulator of AR signaling in two PCa cell lines, possibly through 
multiple mechanisms. 
 
Direct interaction between DJ-1 and AR was determined using a yeast two-hybrid 
screen of a cDNA library generated from flutamide-activated HPE cells (Figure 21). The 
interaction was confirmed in LAPC4 cells via co-IP showing that the endogenous 
proteins interact (Figure 21C-D). Multiple yeast two-hybrid screens have been performed 
to identify DJ-1 binding partners, but AR has never been reported among them (94, 96-
98, 118). DJ-1 was shown to interact with the apoptotic protein Daxx when a human 
brain cDNA library was screened using this technique.   This interaction was confirmed 
and demonstrated to prevent cellular apoptosis following apoptotic stimuli in neuronal 
cells (94). DJ-1 interacts with PIASx-alpha and DJ-1 Binding Protein (DJBP) (98, 118).  
Both of these proteins are co-repressors of AR.  DJ-1 was shown to interact with both 
proteins in mammalian cells resulting in increased AR transcriptional activity.  Our 
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screen did not identify DJBP or PIASx-alpha, however, this may be due to differences in 
the cDNA libraries and cell lines used. Previous studies were performed in COS and 293 
cells and relied on transient transfection into these AR negative cell lines, while our 
experiments were carried out with prostate cell lines and largely examined endogenous 
proteins.  
 
We demonstrate that the DJ-1:AR interaction is hormonally regulated in both 
LNCaP and LAPC4 cell lines.  Specifically, anti-androgen treatment increases the DJ-
1:AR interaction in both cell lines to a greater extent than DHT (Figure 22).  
Immunofluorescence also demonstrates that hormonal treatment increases the co-
localization between DJ-1 and AR in LNCaP cells (Figure 23C and D).  Co-localization 
was not quantified from immunofluorescent images in LAPC4 cells due to low AR levels 
except after DHT treatment.   
 
Further, both androgens and anti-androgens increased nuclear localization of DJ-
1, providing a potential mechanism for DJ-1 regulation of AR in the nucleus. 
Interestingly, increased nuclear DJ-1 is observed after androgen and anti-androgen 
treatment in both LAPC4 and LNCaP cell lines (Figure 23A-C). Nuclear/cytoplasmic 
extracts and immunofluorescence demonstrate the increase in DJ-1 and AR expression 
(Figure 23A-C) and co-localization (Figure 23D) following treatment. In LAPC4 cells, 
DHT, OH-flutamide, and bicalutamide treatment result in approximately equal levels of 
nuclear DJ-1 (Figure 23A).  However, in LNCaP cells, DHT treatment results in higher 
levels of nuclear DJ-1 than either OH-flutamide or bicalutamide (Figure 23B-D). 
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Additionally, DHT and bicalutamide treatment resulted in DJ-1:AR co-localization 
throughout the nucleus, whereas DJ-1:AR appeared to concentrate just inside the nuclear 
perimeter after OH-flutamide treatment. These differences may be due to the well 
characterized AR T877A substitution mutation in LNCaP cells (137) (72) (84). This 
mutation allows flutamide to exhibit agonist activity, however, since this mutation causes 
an AR conformational change, it could inhibit the interaction with DJ-1.  Alternatively, 
the differences between the LNCaP and LAPC4 cells may be due to differences in 
signaling pathways between the cell lines.  For example, DJ-1 has been shown to 
antagonize the tumor suppressor, PTEN (95).  LNCaP cells lack functional PTEN (30) 
while the PTEN pathway is intact in the LAPC4 cell line (27).  Since the exact role of 
DJ-1 in the PTEN pathway remains unclear, it is possible that loss or inactivation of 
members of this pathway alter the function of DJ-1. 
 
Modulation of DJ-1 expression regulates AR transcriptional activity in LAPC4 
cells suggesting that over-expression of DJ-1 could facilitate AR activation in the absence 
of androgens (Figure 24A and C). We previously identified DJ-1 as a protein which is up-
regulated with anti-androgen treatment in primary HPE and LNCaP cells. Currently, 
TMA analysis of DJ-1 expression demonstrates that DJ-1 does not change with Gleason 
pattern, but increases significantly after 6 months of ADT (Figures 25 and 26). This 
correlates with our previous data and is the first reported large scale evaluation of DJ-1 
expression in PCa. Additionally, the importance of this study should be emphasized, due 
to the difficulty in obtaining tissue samples from patients who received ADT prior to 
surgery. However, the current study did not evaluate DJ-1 staining intensity in relation to 
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the patient’s overall PCa risk which is determined by clinical parameters such as PSA and 
total Gleason score.  This is a potential future direction as well as determining whether 
DJ-1 staining intensity correlates with PCa recurrence or time-to-recurrence.  
 
Current and previous data demonstrate that anti-androgens stabilize DJ-1, increase 
nuclear localization, and increase the interaction between DJ-1 and AR. Further, DJ-1 
expression increases in patients who received more than 6 months ADT providing 
clinical evidence that DJ-1 is involved in AIPC. Taken together, these data demonstrate 
that DJ-1 is a novel AR binding protein that may be part of a group of genes regulated by 
anti-androgens. Factors, such as DJ-1, that are regulated by anti-androgens may increase 
following anti-androgen therapy to activate AR in the absence of androgens. Future 
studies are needed to identify other anti-androgen regulated genes and to better 
understand the role they play in PCa progression and activation of AR signaling in the 
absence of ligand. 
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CHAPTER V 
ADDITIONAL STUDIES TO DETERMINE THE FUNCTION OF DJ-1 
 
Introduction 
 
 The following sections provide additional data that was generated during the 
course of the DJ-1 study.  These observations could potentially be developed into studies 
that investigate the regulation of DJ-1 expression and function in prostate cancer.  
Furthermore, the yeast two-hybrid system identified other putative DJ-1 binding proteins 
which could provide novel insights into the role of DJ-1 in prostate cancer. 
 
DJ-1 Promoter 
 One unexplored area of the DJ-1 field is transcriptional regulation of this multi-
functional protein.  A 2kb region of the human DJ-1 promoter was entered into the NCBI 
database (accession number AB045294) but has not been characterized fully.  The 
transcription initiation site was identified and it was determined that DJ-1 expression is 
dependent on the Sp-1 transcription factor in HeLa cell extracts (152). However, other 
transcription factor binding sites were  not identified.  We performed sequence analysis to 
identify potential transcription factor binding sites that are known to be important in PCa.  
We included the consensus binding sites for AR, Androgen Responsive Elements (ARE), 
AP-1, Foxa1, and NF-1 in the initial search of the promoter sequence. 
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Prostate Cell Lines  
Over the last several decades, multiple PCa cell lines have been generated.  These 
cell lines vary between site of origin and molecular characteristics.  For example, some 
cells retain AR expression, but most lose AR and PSA expression after being cultured in 
vitro. Further, some cell lines will grow in a mouse host, while others either do not grow, 
or grow so quickly that in vivo studies are difficult.  Each cell line has pros and cons 
depending on the question under study, and for these reasons most labs have multiple cell 
lines that are used for experiments.  DU145 cells were one of the first PCa cell lines 
generated and are still used today.  DU145 cells originated from a brain metastasis and 
were first published in 1977 (135, 153).  Several years later, the LNCaP and PC3 cell 
lines were generated from a lymph node and brain metastasis, respectively (135, 153-
155).  While DU145 and PC3 cells do not express AR at the protein level, LNCaP cells 
were unique at the time because they retained AR expression (153, 154) (155). Further 
study of the LNCaP cell line revealed that although they are AR-positive and androgen-
responsive, they harbor a well characterized mutation in the ligand binding domain, 
T877A, which was discussed previously (Chapters III and IV) (72, 73, 135, 137, 156).  
Since the late-seventies and early-eighties, many more PCa cell lines have been derived.  
The LAPC4 cell line is a more recent addition to the available PCa cell lines.  This cell 
line was discussed previously (Chapter IV) and has been used in recent years by several 
groups studying AR.  LAPC4 is one of the few PCa cell lines that is androgen-dependent 
and expresses wild-type AR (135, 147).  Our lab utilizes the above PCa cell lines as well 
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as several other non-prostate cell lines that were screened for DJ-1 expression.  Table 3 
summarizes some of the important characteristics of these cell lines. 
 
 
Table 4:  Cell Lines That Express DJ-1.  
Cell Line Site of origin Year 
published 
AR status Androgen 
Regulation 
References 
DU145 PCa brain 
metastasis 
1977 (-) Androgen-
independent 
(153, 154) 
PC3 PCa bone 
metastasis 
1978 (-) Androgen-
independent 
(155) 
LNCaP PCa lymph 
node 
metastasis 
1980 (+) 
T887A 
Androgen-
responsive 
(157, 158) 
LAPC4 PCa lymph 
node 
metastasis 
1997 (+) wild-
type 
Androgen-
dependent 
(147) 
BPH-1 Benign 
prostate 
1995 (-) Androgen-
independent 
(159) 
HPET Primary PCa 
tumor 
2007 (-) Androgen-
independent 
(160) 
HeLa Cervical 
cancer 
1951 (-) Androgen-
independent 
 
HeLa 
AR 
Cervical 
cancer 
 (+) 
exogenous 
Androgen-
independent, 
androgen-
responsive 
(161) 
NIH-3T3 Mouse 
fibroblast 
1969 (-) Androgen-
independent 
(162) 
 
 
Mouse Prostate and Lady Mouse Model for Prostate Cancer 
Although far from identical, the mouse prostate and urogenital system is similar 
enough to humans to make it a convenient model system. Both species have prostates 
surrounding the urethra that function similarly to contribute fluid to semen. After birth, 
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mouse epithelial/stromal cellular differentiation occurs in the first 2-3 weeks when 
distinct populations of secretory luminal epithelial cells, basal epithelial cells, and 
stromal cells are formed (5).  Briefly, in addition to cellular differentiation, branching 
morphogenesis occurs after birth whereby the prostatic ducts proliferate at the distal tips. 
During branching morphogenesis, the once solid epithelial cords branch to form the 
complex network of glands (reviewed in (5)).  By 5 weeks of age prostatic differentiation 
is complete, resulting in the adult mouse prostate and mice are sexually mature at 6 
weeks of age. Unlike human prostate, the adult mouse prostate is composed of multiple 
lobes – the dorsal (DP), lateral (LP), ventral (VP), and anterior (AP).  The dorsal and 
lateral lobes are connected and surround the urethra (Figure 27) and are sometimes 
experimentally examined as a single lobe which is referred to as the dorso-lateral prostate 
or DLP. Due to lobe-specifc patterns of branching, each lobe has a distinct shape (Figure 
27).  In addition to shape, there are differences in gene expression, morphology, 
epithelial-infolding, and secretory-activity between prostatic lobes (5).  
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Figure 27: Urogenital System of the Adult Male Mouse Two views are shown. 
The four lobes of the prostate are shown which are located adjacent to the bladder 
and surrounding the urethra.  Other male urogenital glands include the seminal 
vesicles, ductus deferens, ampullary gland, epididymus, testis, and bulbourethral 
gland. Figure from (50). 
 
 
There are multiple mouse models available to study human PCa progression 
(reviewed in (115)).  Due to the heterogeneous nature and multi-step progression of PCa, 
it has been difficult to generate a single mouse model that covers all aspects of disease 
progression.  Many PCa models have been generated by over-expression, loss, or 
mutation of a single gene, but another widely studied series of models was generated by 
the introduction of the Simian Virus 40 (SV40).  The Large-T and small t-antigens are the 
two most studied viral proteins that compose SV40. Although each protein has multiple 
functions, a major function of Large-T is inactivation of the tumor suppressors p53 (163) 
and Rb (164) in order to promoter viral replication and cellular transformation (165).  
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Small-t antigen has mitogenic activity that facilitates transformation such as activation of 
the Wnt and MAP Kinase pathways (165).  
 
 
 
Figure 28 The Lady Mouse Model for Prostate Cancer Progression The large 
probasin promoter targets the SV40 Large-T antigen to the mouse prostate 
resulting in inhibition of p53 and Rb and development of localized PCa.  The 
normal mouse prostate and a transgenic prostate are shown with different 
prostatic lobes and urogenital organs identified. BL=bladder, UR= urethra, AP 
=anterior prostate, VP=ventral prostate, LP=lateral prostate, DP=dorsal prostate, 
SV=seminal vesicles . 
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Several mouse models have been generated using the SV40 Large-T and small-t 
antigens.  The Lady model was generated by targeting the Large-T antigen to the CD-1 
mouse prostate using the probasin promoter (LPB-TAg) (Figure 28) (166, 167).  Multiple 
LPB-TAg lines were generated and characterized (166), but this project utilized only the 
12T-7f line. The 12T-7f transgenic line has been extensively characterized and the 
prostates of these mice develop multifocal lesions that express TAg.  12T-7f tumors 
progress to resemble human low-grade PIN (LGPIN), marked by areas with mild nuclear 
atypia, and later progress to more pronounced nuclear atypia which resembles human 
high-grade PIN (166).  These tumors do not metastasize to distant sites, although 
localized invasion has been reported (166). Figure 28 demonstrates the size of the 12T-7f 
tumors as compared to age-matched wild-type prostate, indicating the location of seminal 
vesicles (SV), AP, DP, LP, VP, urethra (UR), and bladder (BL). These tumors are 
androgen-dependent demonstrated by tumor regression following castration, and 
exogenous androgen treatment that causes tumor re-growth (166).   Although these 
tumors remain androgen-dependent today and the molecular characteristics are similar to 
those originally reported, there have been noticeable changes to the line over time.  
Multiple labs have seen an increase in tumor on-set and more rapid tumor growth.  For 
example, when the line was originally characterized, male mice would routinely live past 
20 weeks of age before the tumor-burden was life threatening, but today, tumor growth 
has increased and mice are euthanized at 15 weeks of age before they succumb to tumor-
burden due to bladder and bowel obstruction (unpublished observations, Kasper and 
Matusik laboratories).  The reasons behind this increase in tumor growth are unknown, 
but could be due epigenetic events. For the purposes of this study, it should be noted that 
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all 12T-7f male mice have large prostate tumors by 10-11 weeks of age, while the 
prostates of mice younger than 6 weeks are closer to phenotypically normal prostates. 
 
Yeast Two-Hybrid System to Identify DJ-1 Binding Partners 
The MatchMaker™ System from Clontech was used to identify novel DJ-1 
binding partners in PCa.  This screen was described previously (Chapters II and IV).   
Full-length DJ-1 was used to screen a cDNA library generated from flutamide-activated 
primary HPE cells. AR was identified as a novel DJ-1 binding partner, which was 
confirmed and became the major focus of this research project because of the essential 
role of AR and androgen signaling in PCa (Chapter IV).  In addition to AR, 18 other 
genes were identified as putative DJ-1 binding partners.  There is a lack of information on 
the DJ-1 signaling pathway in PCa, and future research is required to verify the 
interaction between DJ-1 and these potential binding partners to better elucidate the DJ-1 
signaling pathway. 
 
 
Results 
 
Transcriptional Regulation of DJ-1 
Currently there is no published literature on factors that transcriptionally regulate 
DJ-1. We performed a sequence-based analysis of the human DJ-1 promoter region 
(NCBI accession number AB045294) using the web-based programs, Transcription 
Factor Search (TF SEARCH) (http://www.cbrc.jp/research/db/TFSEARCH.html) and 
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Basic Local Alignment Search Tool (BLAST) (http://www.ncbi.nlm.nih.gov/BLAST/), in 
order to determine putative transcription factor binding sites. Using these programs, we 
identified multiple putative binding sites, but no exact matches to consensus sequence 
binding sites.  Imperfect sites include AP-1 (binding sites also known as phorbol 12-O-
tetradecanoate-13-acetate (TPA) response elments), NF1, HNF-alpha, and multiple 
Androgen Recognition Elements (ARE)/Androgen Receptor Binding Sites (ARBS). 
Figure 29 illustrates the 2119 base pairs of the DJ-1 promoter examined.  The percent 
homology is indicated for potential binding site.  The top sequence is the consensus 
binding site and the bottom sequence is the DJ-1 promoter. Identical pairing is indicated 
in red. These potential binding sites were of interest for a number of reasons.  AP-1 is a 
well known transcription factor that is composed of Jun and Fos (168) and is involved in 
multiple aspects of tumor progression including proliferation and inflammation (169) 
(168). Nuclear Factor-1 (NF-1) is part of a heterogeneous family of transcription factors 
that range in size and function (170-174).  We included the well-conserved NF-1 binding 
site in this analysis because it has been shown to regulate milk proteins in mammary 
gland and is associated with hormonal regulation (170, 175, 176).  Since mammary tissue 
is hormonally regulated through nuclear receptor action, there are many parallels to 
hormonal regulation and signaling cross-talk between breast and prostate (177, 178). 
FoxA1 is also known as hepatocyte nuclear factor 3 alpha, and is a member of the 
forkhead class of DNA-binding proteins.  FoxA1 and other Fox proteins were originally 
described in development of endodermally derived tissues and in the regulation of liver-
specific transcripts such as albumin (179).  A member of our group discovered that 
FoxA1 is required for AR-mediated gene activation and that FoxA binding sites flank 
 110 
AREs in the promoter region of PSA and probasin (180). Further, FoxA1 was expressed 
in human adenocarcinoma regardless of Gleason score, while FoxA2 was found only in 
neuroendocrine PCa (181).  FoxA consensus binding sites were included in this analysis 
because at the time it was unknown whether DJ-1 was an androgen regulated gene. If 
FoxA binding sites flanked AREs as in PSA and probasin, it would add confidence that 
the sites were functional.   
 
Figure 29: The Human DJ-1 Promoter Potential transcription factor binding 
sites were identified based upon sequence similarity.  The percent homology is 
shown for each site.  Top line of sequence is the consensus/published site and the 
bottom line is the DJ-1 sequence.  Identical base pair matches are in red.  Known 
Sp-1 and CAP sites are listed. 
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In order to determine whether any of the putative sites are functional, we planned 
to make truncations of the DJ-1 promoter region and clone the fragments upstream of the 
luciferase reporter.  These reporter plasmids would be used to determine which region of 
the promoter was required for activity.  Once identified, the region of interest could be 
used for band-shift assays with the appropriate purified transcription factors to determine 
an interaction. Transfection assays would be utilized to determine the effects of these 
transcriptional regulators on DJ-1 expression. However, due to difficulties cloning the 
region of the DJ-1 promoter, and a change in the direction of the project, these 
experiments were not completed. 
 
Characterization of DJ-1 Expression in Prostate Cancer Model Systems  
 
Expression in human PCa cell lines 
 Initially, there was little information on the expression pattern of DJ-1 in model 
systems for PCa including established human PCa cell lines and mouse models.  Our lab 
uses a variety of cell lines, and it was important to determine the DJ-1 expression pattern 
in these cell lines.   
 
 The cell lines commonly used in our laboratory include: NIH 3T3, LNCaP, 
DU145, PC3, BPH1, LAPC4, HeLa, HeLa AR, and HPET (primary HPE cells 
immortalized with human Telomerase Reverse Transcriptase (hTERT)). Total protein 
was extracted from each of these cell lines at low and high confluency and used for 
Western Blot.  This experiment revealed that DJ-1 is expressed in all cell lines currently 
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available to our laboratory and that increased confluency appeared to increase DJ-1 
expression (Figure 30).  Human beta-actin was used as a loading control, but after this 
experiment we determined that the levels of beta-actin vary between cell lines and is not 
a suitable loading control for this type of experiment.  Nevertheless, we demonstrate that 
DJ-1 is widely expressed in available cell lines. 
 
 
Figure 30: DJ-1 Expression in Available Cell Lines  Western blot for DJ-1 
expression in cell lines at high and low confluency.  Human beta-actin used as a 
loading control. 
 
 
Over-expression of DJ-1 Does Not Affect Growth or Motility of LNCaP and 
DU145 Cells 
 
 Based upon previous published data identifying DJ-1 as an oncogene, we over-
expressed DJ-1 in the LNCaP and DU145 cell lines using the ViraPower lentiviral 
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expression system (Invitrogen). Increased expression of DJ-1 transformed both cell lines 
to some degree, as seen by formation of small colonies (Figure 31), However, it did not 
alter motility or proliferation in either cell line (data not shown).  This experiment was 
repeated using a higher multiplicity of infection (MOI) in an attempt to over-express DJ-
1 by 50 and 100 fold the endogenous level.  This experiment was performed in LNCaP 
cells since they express endogenous AR.  For an unknown reason, the transgene was 
expressed, but not at 50 or 100 fold as expected (Figure 32).  This could be due to 
toxicity from using this level of virus, and only those cells infected with less DJ-1 virus 
survived. Even though these cells did not express higher levels of DJ-1 than observed 
with the initial experiments, proliferation assays were performed, but showed no 
difference between vector control and DJ-1 over-expressing cells. These experiments 
imply that in LNCaP cells DJ-1 could potentially function as an oncogene to transform 
cells, but that DJ-1 does not play a role in cell migration or invasion. 
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Figure 31: Over-expression of DJ-1 Causes Colony Formation in LNCaP and 
DU145 cells. Overexpression of DJ-1 in LNCaP and DU145 cells causes colony 
formation consistent with published reports in NIH 3T3 cells (93). 
 
 
 
 
 
 
 
Figure 32: Expression of V5-tagged DJ-1 in LNCaP cells.  LNCaP cells were 
infected at 50 and 100 MOI concentration of virus with either an empty vector 
(V50  and V100) or V5-DJ-1 plasmid (D50 and D100).  Anti-DJ-1 antibody 
recognizes both tagged and un-tagged DJ-1.  
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Development of a Tetracycline (TET) Inducible DJ-1 shRNA Cell Line 
 DJ-1 is a highly conserved ubiquitiously expressed protein.  Throughout the 
course of this research project, a DJ-1 negative cell line or tissue could not be found.  
Therefore, we sought to generate a human prostate cancer cell line that stably expressed a 
shRNA targeted against DJ-1.  These cells could then be xenografted into SCID mice and 
compared to the parental cell line to determine the effect of DJ-1 on tumor growth in 
vivo.   
 
 LNCaP TET-ON cells that stably express the Tetracycline Repressor and 
Tetracycline Operon were obtained from Dr. Renjie Jin in Dr. Robert Matusik’s 
laboratory at Vanderbilt.  A viral mediated TET-inducible DJ-1 shRNA plasmid was 
purchased from Genscript.  Figure 33 illustrates the features of this plasmid.  When 
LNCaP TET-ON cells are infected with the TET-inducible DJ-1 shRNA plasmid, and 
treated with doxycycline, shRNA expression is induced, and DJ-1 expression should be 
knocked-down.  After infection, cells expressing the DJ-1 shRNA plasmid were FACS 
sorted using the GFP marker.  These cells were then treated with doxycycline (Dox) to 
induce shRNA expression, harvested, and analyzed by Western Blot.  Treatment with 10 
ug/ml doxycyline knocked-down DJ-1 expression to approximately 50% of the non-
targeting control shRNA.  AR expression did not change with modulation of DJ-1, which 
is consistent with previous data (Figure 34 and Figure 24, chapter IV).  Although these 
cells were not used further in the present study, they are an available tool for future DJ-1 
research. 
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Figure 33: Tetracycline-inducible shRNA system. A Tet-inducible shRNA 
plasmid purchased from Genescript and a cartoon describing the Tet-inducible 
expression system. 
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Figure 34: Knockdown of DJ-1 Using a Tet-Inducible shRNA in LNCaP 
Cells  LNCaP TET-ON cells were stably infected with a cassette for either an 
inducible control shRNA or inducible DJ-1 shRNA. Cells were treated with two 
concentrations of doxycycline (dox) to induce shRNA expression.  DJ-1 
expression decreases following a high dose of dox, while AR is unchanged.  
GAPDH loading contol. 
 
 
Expression in CD-1 and 12T-7f mice 
 To determine whether DJ-1 was expressed in mouse prostate, total RNA was 
extracted from 6 week and 15 week wild-type (CD-1) and LADY 12T-7f dorsal prostates, 
reverse transcribed, and used for RT-PCR.  cDNA from LNCaP cells was used as a 
positive control for the PCR reaction.  DJ-1 was expressed at the mRNA level at both 
time points in CD-1 and 12T-7f mice (Figure 35).  Western Blot of total protein from 3 
and 15 week CD-1 dorsal prostates and 13 week 12T-7f  mice confirmed this expression 
at the protein level (Figure 35).  In addition to dorsal prostates, the NeoTAg 1 and 2 cell 
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lines were included in this analysis.  These cell lines were generated and obtained from 
Dr. Yongquing Wang in the Matusik laboratory at Vanderbilt. The NeoTAg cell lines 
were derived from the 12T-7f prostate tumors and have been previously described (182). 
As expected, DJ-1 is expressed in these mouse PCa cell lines as well as in the primary 
12T-7f tumors.  
 
 
Figure 35: DJ-1 Expression in Mouse Dorsal Prostates and Cell Lines. A) RT-
PCR shows that DJ-1 is expressed in wild-type and 12T-7f prostates. B) Western 
blot analysis confirms DJ-1 expression and demonstrated an increase in 12T-7f 
dorsal prostate. NeoTAg 1 and 2 are cell lines that are derived from 12T-7f 
prostate tumors. LNCaP human PCa cell line was used as a positive control.  The 
larger bands at 80 and 50 kDa have not been observed in human cells or tissues 
and may represent mouse-specific post-translationally modified forms of DJ-1. 
 
 
In order to complete the expression profile for DJ-1 in both developing prostate 
and in tumorigenesis, total RNA was extracted from dorsal prostates CD-1 and 12T-7f 
mice at 2, 3, 4, 5, 6, 10, and 15 weeks of age.  Each sample represents a pool of total 
RNA from the individual age group as described (123).  cDNA was prepared and used for 
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quantitative realtime RT-PCR. DJ-1 was expressed at all ages in both CD-1 and 12T-7f 
mice (Figure 36).  Interestingly, DJ-1 expression is higher at all ages in the 12T-7f mice.  
Further, DJ-1 expression peaks at 3-4 weeks in both wild-type and 12T-7f mice during 
prostate differentiation and at 15 weeks in the 12T-7f tumors.   
 
 
 
Figure 36: Real-time RT-PCR Analysis of DJ-1 Expression in CD-1 and 12T-
7f Mouse Dorsal Prostates. Realtime RT-PCR analysis of DJ-1 expression at 
different aged CD-1 and 12T-7f mice. DJ-1 relative expression was determined by 
normalization to 18S rRNA control.  CD-1 solid blue bars, 12T-7f hatched bars.  
Each bar represents mean +/- SEM. 
 
 
Immunohistochemical analysis of 3- and 15-week CD-1 and 15-week 12T-7f 
dorsal prostates confirmed the real-time RT-PCR results indicating that DJ-1 expression 
was higher in 12T-7f tumors than in wild-type adult prostate (Figure 37).  Additionally, 
DJ-1 subcellular localization changes from predominantly cytoplasmic in the 3-week old 
CD-1 dorsal prostate to nuclear in the 15-week adult growth-quiescent prostate.  DJ-1 
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was highly expressed and mainly cytoplasmic in the adult 12T-7f prostate. Additional 
experiments determined that DJ-1 was cytoplasmic regardless of age in the 12T-7f mice 
(data not shown). 
 
 
Figure 37: Immunohistochemical Analysis of DJ-1 Expression and Sub-
cellular Localization in CD1 and 12T-7f Mouse Dorsal Prostates.  
Immunohistochemical staining for DJ-1 on dorsal CD1 and 12T-7f prostate lobes 
shows increased DJ-1 expression in the 3 wk developing prostate and in the 12T-
7f prostate tumors. Subcellular DJ-1 localization changes from  predominantly 
cytoplasmic in the  3 wk CD-1 prostate to predominantly nuclear in the 15 wk 
adult prostate.  Interestingly DJ-1 is predominantly cytoplasmic regardless of age 
in 12T-7f prostates.  Low (top) and high  (bottom) magnifications for each sample 
are shown. 
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Hormonal Regulation of DJ-1 Expression in 12T-7f Mice 
 Total RNA was extracted from the dorsal prostates of CD-1 and 12T-7f mice that 
had been surgically castrated for 1, 2, 4, or 12 weeks and used for realtime RT-PCR 
analysis of DJ-1 expression.  After castration, DJ-1 expression is maintained in both CD-
1 and 12T-7f mice (Figure 38).  DJ-1 expression peaked after 2 weeks of castration in the 
12T-7f prostates, and returned to basal levels by 4 weeks post-castration.  Error bars 
represent the mean +/-SEM between samples from different mice.  For intact mice and 
the 12-week post-castration sample, there are no error bars because only one sample was 
available.  However, this experiment was repeated twice with the same trend.  
 
Figure 38: Real-time RT-PCR Analysis of DJ-1 Expression After Castration 
in CD-1 and 12T-7f Dorsal Prostates Real-time RT-PCR analysis of DJ-1 
expression in the dorsal prostates post-castration.  Sample and time after 
castration is indicated on the x-axis.  Relative DJ-1 expression afer normalization 
to 18S rRNA in micromoles on the y-axis. DJ-1 expression increases in 12T-7f 
mice 2 weeks after castration before falling to basal levels at 4 weeks post-
castration. 
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Table 5:  Putative DJ-1 Binding Partners from Yeast Two-Hybrid Screen The gene 
name is listed along with NCBI protein accession number. The number of times the gene 
was represented in the screen is listed as the number of “clones” identified. The length of 
the exact alignment between the experimental sequence and the published sequence is 
listed in base pairs (bp). Any known interesting functions that might be relevant in PCa 
are listed on the right. 
 
Gene NCBI protein  clones bp Interesting Functions 
Enolase 1 NP_001419 1 893 Tumor suppressor, perturbs cell 
proliferation by inhibtion of cyclinA 
and B1 (183) 
Carcinoembryonic antigen-
related cell adhesion 
molecule 5 (CEACAM5) 
NP_004354 2 362 Cell adhesion; inhibition in colon 
cancer increases metastasis (184) 
P-cadherin NP_001784 8 823 Associated with aggressiveness in 
breast cancer (185) 
NOL1/Sun domain 
member 5 (NSUN5) 
NP_060514 1 647 Uncharacterized, has similarity to 
p120(NOL1) 
Procollagen-lysine, 2-
oxoglutarate 5-dioygenase 
1 (PLOD-1) 
NP_000293.2 1 211 Membrane-bound in endoplasmic 
reticulum; hydroxylation of collagen-
like peptides 
Carboxypeptidase D NP_001295.2 1 829 metallopeptidase 
Myosin 1C NP_001074248 1 397 Non-conventional myosin isoform 
Makorin 2 NP_054879.3 1 441 Uncharacterized ring-finger protein 
Sirtuin 7 NP_057622.1 1 273 Unknown function, increased in 
breast cancer (186) 
Ubiquitin-specific Protease 
15 
NP_006304.1 3 804 Degradation of ubiquitin 
LDL related protein 1 
(LDP1)/ApoE Receptor 
NP_002323.1 1 466 Apolipoprotein E receptor 
Solute Carrier Family 3, 
member 2 (SLC3A2) 
NP_001012679.1 2 549 Membrane bound, regulates integrin-
dependent signaling  
Filamin B NP_001448.2 1 232 Cell adhesion/Actin-binding protein 
NADH-Ubiquinone 
Oxidoreductase Fe-S 
NP_002487.1 1 797 unknown 
FK506 BP9 NP_009201.2 1 397 unknown 
Co-stimulatroy B7 
molecule CD276 
NP_001019907.1 1 468 Signaling  
ADAM15 NP_003806 1 760 Cell adhesion, associated with 
aggressive prostate and breast cancer 
(187) 
Plexin A1 NP_115618 1 801 Impairs chemotaxis (188) 
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Additional Putative DJ-1 Binding Partners in Prostate Cancer Epithelial Cells 
 
 After sequence analysis, multiple putative DJ-1 binding proteins were identified. 
In addition to AR, 18 other proteins were identified in the screen. Table 4 lists the genes 
identified, the NCBI accession number, the number of times identified in the screen, the 
length of the exact alignment with the published gene sequence in base pairs, and known 
functions of the protein.  Several proteins were previously implicated in cancer.  For 
example, inhibition of Carcinoembryonic antigen (CEA) in colon cancer inhibits 
apoptosis and increases metastasis (reviewed in (189)).  ADAM 15 (A Disintegrin and 
Metallopeptidase 15) is a transmembrane glycoprotein that is involved in cell adhesion.  
ADAM 15 is over-expressed in breast and prostate adenocarcinoma and may play a role 
in metastasis (187). P-cadherin is another cell adhesion molecule that has been implicated 
in PCa.  P-cadherin expression has been correlated with breast cancer aggressiveness 
(185). Other potential DJ-1 binding partners may be important in PCa, but have not been 
studied in prostate. PLOD 1 (Procollagen-lysine 1,2 oxoglutarate 5-dioxygenase 1) was 
identified as a potential AR binding protein in an independent yeast two hybrid screen 
performed in our laboratory (unpublished data).  Currently, the role of PLOD 1 in PCa is 
unknown, but it could mediate AR signaling and form a heterotrimeric complex with DJ-
1 and AR.  Finally, there were several proteins identified that have not been characterized 
including Sirtuin and FK506 binding protein 9 (FKBP9).  Interestingly, another protein in 
the FK506 binding protein family, FKBP52, is a heat-shock binding protein implicated in 
regulation of GR and AR. Male FKBP52 null mice exhibit dysgenic prostates and 
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ambiguous external genitalia. (190, 191).  The FK506BP family is large and diverse, so it 
is unknown at this time whether FKBP9 plays a role in PCa or AR signaling. 
 
 Initial experiments were performed to determine the expression of several genes 
of interest from the yeast two hybrid screen.  Genes were chosen based upon available 
reagents and interest to existing projects in the laboratory.  Based upon these criteria, AR, 
PLOD-1, P-cadherin, and FKBP9 were examined.  Expression profiles for these genes 
were determined in cell lines available in our lab. RT-PCR was performed using cDNA 
from the prostate derived LNCaP, DU145, BPH1, PC3 cell lines as well as the cervical 
cancer cell line HeLa AR.  HeLa AR cells have a stably integrated human AR and have 
been used for many years to study AR signaling.  Figure 39 shows that P-cadherin is 
expressed at the mRNA level in all cell lines tested.  FKBP9 was present in all cell lines 
except LAPC4. PLOD-1 is expressed in all cell lines tested except for DU145. As 
expected, AR was expressed more highly in LNCaP, HeLa AR, and LAPC4 cells which 
express functional AR protein.  PC3, DU145, and BPH1 cells were weakly positive at the 
mRNA level for AR, but these cell lines do not have functional protein (135). DJ-1 was a 
positive control since it was known to be expressed in all of the cell lines examined.  
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Figure 39: Expression of Genes of Interest From DJ-1 Yeast Two-Hybrid 
Screen RT-PCR of the indicated cell lines for several of the genes of interest.  A) 
1= FKBP9, 2=P-cadherin, 3=DJ-1, 4=PLOD-1 (upper band in LNCaP and HeLa 
AR cells is expected size), 5=AR, 6= negative control.  B) Loading order is 
different than A.  Here, 1=PLOD-1, 2=AR, 3=FKBP9, 4=P-cadherin, 5=PSA 
(control), 6= negative control. Annealing temperatures for some primer pairs are 
not optimized, which resulted in multiple bands. 
 
 After expression analysis was performed for the genes of interest, we wanted to 
determine whether modulation of expression of the genes of interest affected AR 
transcriptional activity since DJ-1 interacts with AR.   To address this, commercial 
pooled siRNAs directed against PLOD-1 and FKBP9 were purchased from Dharmacon to 
knockdown expression of these genes and perform androgen-regulated luciferase assays 
(described in chapter IV).  Initial transfections of siRNAs into LNCaP and HeLa AR cells 
demonstrated that both siRNA pools were moderately effective in knocking down PLOD-
1 and FKBP9 at the mRNA level, but luciferase assays after down-regulation of PLOD-1  
and FKBP9 showed very low AR activity, even in the positive control samples. For this 
reason, no conclusions can be drawn from this data (data not shown).  At the time these 
experiments were performed, pooled siRNAs for P-cadherin were not available.  These 
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experiments could be completed in the future to determine whether these are true DJ-1 
binding partners and whether or not they affect AR transcriptional activity.  
 
The list of putative DJ-1 binding partners is varied and includes proteins involved 
in cellular adhesion, signal transduction, and enzymatic reactions.  Although the list of 
potential binding partners is diverse, this was expected based upon the heterogeneous DJ-
1 literature.  DJ-1 has been implicated in multiple diseases and signaling pathways.  The 
interaction between DJ-1 and AR was confirmed (Chapter IV), but 19 other putative 
binding partners must be studied further. Future research should validate the potential 
binding partners and better define the precise role of DJ-1 in the pathways identified. 
 
Discussion 
 Currently, there are still many aspects of the role of DJ-1 in PCa that are not 
understood.  This project has provided information in multiple areas relating to DJ-1: 
potential transcriptional regulation of DJ-1, DJ-1 expression and regulation in PCa model 
systems, and additional putative binding partners.   
 
 Transcriptional regulation of DJ-1 is a completely novel area of research in the 
DJ-1 field.  We used sequence analysis programs to identify potential transcrition factor 
binding sites in a 2kb region of the human DJ-1 promoter.  This analysis identified 
multiple putative sites, but none with exact homology to the published binding site.  
Additional analysis is required to determine whether any of these putative sites are 
functional.  Based upon data presented in previous chapters, however, it is unlikely that 
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the androgen receptor binding sites are functional.  Specifically, the increase in DJ-1 
expression after treatment with androgens and anti-androgens is due to protein 
stabilization rather than increased transcription of DJ-1 (Figure 20).  Furthermore, 
treatment with TPA, which activates AP-1, did not increase DJ-1 protein levels in LNCaP 
cells. This result may indicate that DJ-1 is not regulated by the AP-1 transcription factor, 
however, AP-1 activation often requires other factors, so there is still a possibility that 
AP-1 regulates DJ-1. A complete analysis after TPA treatment was not performed, nor 
were additional experiments to confirm the NF-1 binding sites. Based upon the multiple 
roles of DJ-1 in different tissues, it is likely that transcriptional regulation varies between 
tissues, and that there are additional unidentified binding sites in the promoter region.  
 
 Multiple research groups have identified DJ-1 in different model systems and 
tissues.  In accordance with this, we discovered that DJ-1 is widely expressed in PCa 
model systems.  Using RT-PCR, Western Blotting analysis, and Immunohistochemistry, 
we showed that DJ-1 is expressed in multiple human and mouse cell lines as well as in 
normal mouse prostate and in the 12T-7f mouse model (Figures 30, 35-38).  Quantitative 
realtime-RT-PCR determined that DJ-1 is expressed at higher levels in 12T-7f dorsal 
prostate as compared to wild-type prostate.  Further, expression peaks during prostate 
differentiation and tumorigenesis, implying that DJ-1 is involved in both processes 
(Figure 36) corresponding to our data on DJ-1 in human PCa.  Interestingly, DJ-1 is 
differentially expressed in the cytoplasm and nucleus of wild-type CD-1 dorsal prostates 
(Figure 37).  DJ-1 was predominantly cytoplasmic in 3 week-old developing prostate, but 
was mainly nuclear in the 15 week old growth quiescent gland.  DJ-1 was predominantly 
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cytoplasmic regardless of age in the 12T-7f dorsal prostate.  This  suggests that DJ-1 may 
function similarly during prostate differentiation and tumorigenesis and that sub-cellular 
localization may determine or affect DJ-1 activity.  Currently it is unknown what factors 
regulate DJ-1 sub-cellular localization.  We have observed differential localization in the 
LNCaP and LAPC4 cell lines following hormonal treatment (Figure 23).  It is possible 
that DJ-1 is transported between sub-cellular compartments as part of a multi-protein 
complex.  We showed that DJ-1 binds AR, which translocates to the nucleus after 
hormonal treatment.  Since DJ-1 binds AR and DJ-1:AR co-localization increases after 
hormonal treatment, it is possible that DJ-1 is complexed with AR during nuclear 
translocation. Another important aspect of DJ-1 differential sub-cellular localization is 
that location may determine which proteins DJ-1 interacts with, and subsequently, what 
pathways/cellular processes DJ-1 regulates. 
 
 The DJ-1 yeast two-hybrid identified multiple putative DJ-1 binding partners.  
Since DJ-1 is differentially expressed in the nucleus and cytoplasm, it could interact with 
proteins in both cellular compartments.  Several cell adhesion proteins were identified in 
the yeast two-hybrid screen, including ADAM 15 and P-cadherin.  Both proteins are 
membrane bound, but it is possible that DJ-1 binds the intracellular portion.  PLOD1 is 
also membrane bound, but is localized to the ER.  DJ-1 is expressed throughout the 
cytoplasm, so PLOD1 is a potential cytoplasmic DJ-1 binding partner. The majority of 
the proteins identified in this screen have not been studied in PCa, and some have not 
been studied at all.  Determining the number of real binding partners from this list was 
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beyond the scope of this research project, but hopefully will be a useful starting point for 
future DJ-1 research. 
 
The initial experiments performed to investigate DJ-1 in PCa were varied because 
of the initial lack of published data on DJ-1.  Multiple small projects were started in an 
attempt to elucidate the function of this protein. The role of DJ-1 in modulating AR 
signaling became my project of interest. However, the preliminary data presented in this 
section can be utilized to begin elucidating the regulation of DJ-1 expression in prostate 
cancer. Furthermore, the interaction of DJ-1 with novel binding proteins and the effects 
of DJ-1 sub-cellular localization could provide new insight and avenues of research into 
the functions of this diverse protein.  
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CHAPTER VI 
FUTURE DIRECTIONS AND CONCLUDING REMARKS 
 
 This research project determined that some primary HPE cells from moderately 
differentiated prostate tumors have molecular changes that allowed the anti-androgen 
flutamide to act as an AR agonist.  We found increased levels of DJ-1 and AR after 
flutamide treatment in primary HPE and LNCaP cells and further determined that this 
increase was due to protein stabilization. These results supported known hypotheses for 
mechanisms that would promote androgen-independent disease. Upon further 
investigation, we determined that DJ-1 directly bound the AR and modulated its 
transcriptional activity in prostate cancer cells providing a new mechanism for DJ-1 to 
regulate AR.  The DJ-1:AR interaction was hormonally regulated in two PCa cell lines 
and hormonal treatment increased DJ-1 nuclear localization. The most compelling 
evidence that DJ-1 is involved in PCa progression is that DJ-1 expression increases after 
prolonged ADT in primary tumor samples.  These results provide evidence that DJ-1 may 
play an important role in the progression of PCa to an androgen-independent status and 
fit with previously published accounts of AR co-regulators allowing epithelial cells to 
gain a growth advantage in the presence of low-levels of androgens (48). 
  
 Many aspects of the precise role of DJ-1 in PCa remain unclear.  Although DJ-1 
expression was increased after ADT in primary tumors, this study did not address 
whether the increase in DJ-1 correlated with PCa recurrence or time-to-recurrence. This 
will be an interesting future direction, but unfortunately, may be very difficult to address 
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since the types of samples needed are very hard to obtain, especially in large enough 
numbers to be statistically significant.  Another future direction that will be easier to 
address is whether or not DJ-1 correlates with PCa risk.  This type of study could be 
performed by comparing DJ-1 expression to PSA level, tumor volume, tumor stage, etc. 
This study could be completed more easily because it does not involve samples from 
patients who received therapy or metastatic samples.   
 
 Although we determined that DJ-1 and AR directly interact, we did not determine 
what other proteins are in the complex. There are many known AR-binding proteins, so 
this will likely be a long term project, but one that may elucidate the precise function of 
DJ-1 regulation of AR. Further, there were other proteins identified in the DJ-1 yeast 
two-hybrid that may be important in PCa and AR signaling, but the interaction between 
these putative binding proteins must first be confirmed. This could lead to identification 
of multiple other pathways in PCa that are affected by DJ-1.  Beyond protein-protein 
interactions, DJ-1 acts as a transcription factor in neuronal cells, it is possible that there 
are DJ-1 regulated genes in prostate epithelial cells (113). This will be an interesting 
project, but to date there are no known DJ-1 target genes in prostate. Tyrosine 
hydroxylase, which was identified as the DJ-1 target gene in neuronal cells, is involved in 
dopamine synthesis and is neuron specific so it is unlikely to be expressed in prostate 
cancer.  
 
 Finally, multiple preliminary experiments were performed in mouse prostates 
which may provide interesting future research projects.  DJ-1 expression was increased in 
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12T-7f prostate tumors as compared to wild-type prostates, and also was differentially 
expressed. DJ-1 was cytoplasmic in the 3 week old wild-type prostate and in the 12T-7f 
tumors, but was predominantly nuclear in the 15 week old growth quiescent wild-type 
prostate.  We demonstrated that hormonal treatment changed DJ-1 subcellular 
localization in human PCa cell lines, but it is unknown whether changing hormone levels 
affect the localization of mouse DJ-1.  Since DJ-1 was cytoplasmic regardless of age in 
the 12T-7f mice, it seems more likely that transformation with SV40 Large-TAg affects 
DJ-1 sub-cellular localization. SV40 TAg inhibits p53 (163) and Rb (164), and it is 
possible that alterations in one or both of these signaling pathways affects/regulates DJ-1 
sub-cellular localization.    
 
 This research began to elucidate the role of DJ-1 in PCa. When this project was 
started there were no reports of DJ-1 in prostate, nor was there any indication that DJ-1 
directly interacted with AR. This project shed some light on the potential important role 
of DJ-1 in AIPC or as a marker of PCa risk. Obviously future research will be required in 
order to conclusively answer the questions raised by this research. However, this project 
answered several fundamental questions regarding the function of DJ-1 and provided 
ample preliminary data for future DJ-1 research in PCa.  Therefore, this project 
represents a first-step in the ongoing process of unraveling the multiple functions of 
human DJ-1 in prostate.   
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